Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.
Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.
Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.
Two or more vaccines in a single dosage form.
Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.
Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.
Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.
Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognized by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
Vaccines made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.
Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.
Vaccines or candidate vaccines used to prevent infection with NEISSERIA MENINGITIDIS.
Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.
A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed)
A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)
Vaccines or candidate vaccines containing antigenic polysaccharides from Haemophilus influenzae and designed to prevent infection. The vaccine can contain the polysaccharides alone or more frequently polysaccharides conjugated to carrier molecules. It is also seen as a combined vaccine with diphtheria-tetanus-pertussis vaccine.
An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.
A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS.
Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis.
Vaccines or candidate vaccines used to prevent infection with ROTAVIRUS.
Vaccines or candidate vaccines used to prevent infection with VIBRIO CHOLERAE. The original cholera vaccine consisted of killed bacteria, but other kinds of vaccines now exist.
Vaccines used to prevent TYPHOID FEVER and/or PARATYPHOID FEVER which are caused by various species of SALMONELLA. Attenuated, subunit, and inactivated forms of the vaccines exist.
Immunoglobulins produced in response to VIRAL ANTIGENS.
A live VACCINIA VIRUS vaccine of calf lymph or chick embryo origin, used for immunization against smallpox. It is now recommended only for laboratory workers exposed to smallpox virus. Certain countries continue to vaccinate those in the military service. Complications that result from smallpox vaccination include vaccinia, secondary bacterial infections, and encephalomyelitis. (Dorland, 28th ed)
Vaccines or candidate vaccines used to prevent or treat TUBERCULOSIS.
A live, attenuated varicella virus vaccine used for immunization against chickenpox. It is recommended for children between the ages of 12 months and 13 years.
A vaccine consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and whole-cell PERTUSSIS VACCINE. The vaccine protects against diphtheria, tetanus, and whooping cough.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Vaccines used to prevent infection by MUMPS VIRUS. Best known is the live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had mumps or been immunized with live mumps vaccine. Children are usually immunized with measles-mumps-rubella combination vaccine.
Vaccines or candidate vaccines used to prevent infection with hepatitis A virus (HEPATOVIRUS).
Schedule giving optimum times usually for primary and/or secondary immunization.
Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.
A combined vaccine used to prevent MEASLES; MUMPS; and RUBELLA.
Vaccines or candidate vaccines used to prevent STREPTOCOCCAL INFECTIONS.
Vaccines or candidate vaccines used to prevent ANTHRAX.
A field of biological research combining engineering in the formulation, design, and building (synthesis) of novel biological structures, functions, and systems.
Vaccines or candidate vaccines used to prevent infection with DENGUE VIRUS. These include live-attenuated, subunit, DNA, and inactivated vaccines.
Vaccines using VIROSOMES as the antigen delivery system that stimulates the desired immune response.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
Any vaccine raised against any virus or viral derivative that causes hepatitis.
A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)
Biologically functional sequences of DNA chemically synthesized in vitro.
Vaccine used to prevent YELLOW FEVER. It consists of a live attenuated 17D strain of the YELLOW FEVER VIRUS.
A suspension of killed Yersinia pestis used for immunizing people in enzootic plague areas.
Suspensions of attenuated or killed fungi administered for the prevention or treatment of infectious fungal disease.
A live attenuated virus vaccine of duck embryo or human diploid cell tissue culture origin, used for routine immunization of children and for immunization of nonpregnant adolescent and adult females of childbearing age who are unimmunized and do not have serum antibodies to rubella. Children are usually immunized with measles-mumps-rubella combination vaccine. (Dorland, 28th ed)
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Vaccines that are produced by using only the antigenic part of the disease causing organism. They often require a "booster" every few years to maintain their effectiveness.
Vaccines or candidate vaccines designed to prevent SAIDS; (SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME); and containing inactivated SIMIAN IMMUNODEFICIENCY VIRUS or type D retroviruses or some of their component antigens.
Vaccines or candidate vaccines used to prevent infection with SALMONELLA. This includes vaccines used to prevent TYPHOID FEVER or PARATYPHOID FEVER; (TYPHOID-PARATYPHOID VACCINES), and vaccines used to prevent nontyphoid salmonellosis.
Vaccines using supra-molecular structures composed of multiple copies of recombinantly expressed viral structural proteins. They are often antigentically indistinguishable from the virus from which they were derived.
Vaccines or candidate vaccines used to prevent EBOLA HEMORRHAGIC FEVER.
An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
Combined vaccines consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and an acellular form of PERTUSSIS VACCINE. At least five different purified antigens of B. pertussis have been used in various combinations in these vaccines.
Vaccines or candidate vaccines used to prevent infection with CYTOMEGALOVIRUS.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.
Organized services to administer immunization procedures in the prevention of various diseases. The programs are made available over a wide range of sites: schools, hospitals, public health agencies, voluntary health agencies, etc. They are administered to an equally wide range of population groups or on various administrative levels: community, municipal, state, national, international.
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).
Delivery of medications through the nasal mucosa.
A combined vaccine used to prevent infection with diphtheria and tetanus toxoid. This is used in place of DTP vaccine (DIPHTHERIA-TETANUS-PERTUSSIS VACCINE) when PERTUSSIS VACCINE is contraindicated.
Vaccines used to prevent POLIOMYELITIS. They include inactivated (POLIOVIRUS VACCINE, INACTIVATED) and oral vaccines (POLIOVIRUS VACCINE, ORAL).
Vaccines or candidate vaccines used to prevent or treat both enterotoxigenic and enteropathogenic Escherichia coli infections.
Vaccines or candidate vaccines used to prevent infection with WEST NILE VIRUS.
Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination.
Vaccines or candidate vaccines used to prevent bacillary dysentery (DYSENTERY, BACILLARY) caused by species of SHIGELLA.
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
Sorbitan mono-9-octadecanoate poly(oxy-1,2-ethanediyl) derivatives; complex mixtures of polyoxyethylene ethers used as emulsifiers or dispersing agents in pharmaceuticals.
An attenuated vaccine used to prevent and/or treat HERPES ZOSTER, a disease caused by HUMAN HERPESVIRUS 3.
Antibody-mediated immune response. Humoral immunity is brought about by ANTIBODY FORMATION, resulting from TH2 CELLS activating B-LYMPHOCYTES, followed by COMPLEMENT ACTIVATION.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
A bacterial vaccine for the prevention of brucellosis in man and animal. Brucella abortus vaccine is used for the immunization of cattle, sheep, and goats.
Substances elaborated by bacteria that have antigenic activity.
A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc.
Vaccines or candidate vaccines used to prevent infection by any virus from the family HERPESVIRIDAE.
The forcing into the skin of liquid medication, nutrient, or other fluid through a hollow needle, piercing the top skin layer.
Aluminum metal sulfate compounds used medically as astringents and for many industrial purposes. They are used in veterinary medicine for the treatment of ulcerative stomatitis, leukorrhea, conjunctivitis, pharyngitis, metritis, and minor wounds.
Vaccines or candidate vaccines used to prevent infection with LEISHMANIA.
A subtype of INFLUENZA A VIRUS with the surface proteins hemagglutinin 1 and neuraminidase 1. The H1N1 subtype was responsible for the Spanish flu pandemic of 1918.
The formaldehyde-inactivated toxin of Corynebacterium diphtheriae. It is generally used in mixtures with TETANUS TOXOID and PERTUSSIS VACCINE; (DTP); or with tetanus toxoid alone (DT for pediatric use and Td, which contains 5- to 10-fold less diphtheria toxoid, for other use). Diphtheria toxoid is used for the prevention of diphtheria; DIPHTHERIA ANTITOXIN is for treatment.
DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.
Vaccines or candidate vaccines used to prevent infection with viruses from the genus SIMPLEXVIRUS. This includes vaccines for HSV-1 and HSV-2.
Vaccines or candidate vaccines used to prevent infection with RESPIRATORY SYNCYTIAL VIRUSES.
Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.
Protection conferred on a host by inoculation with one strain or component of a microorganism that prevents infection when later challenged with a similar strain. Most commonly the microorganism is a virus.
Vaccines or candidate vaccines used to prevent conception.
Vaccines or candidate vaccines used to prevent infection with Japanese B encephalitis virus (ENCEPHALITIS VIRUS, JAPANESE).
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
Administration of a vaccine to large populations in order to elicit IMMUNITY.
Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
Vaccines or candidate vaccines derived from edible plants. Transgenic plants (PLANTS, TRANSGENIC) are used as recombinant protein production systems and the edible plant tissue functions as an oral vaccine.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.
Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system.
The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.
A respiratory infection caused by BORDETELLA PERTUSSIS and characterized by paroxysmal coughing ending in a prolonged crowing intake of breath.
Established cell cultures that have the potential to propagate indefinitely.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
The relationship between an elicited ADAPTIVE IMMUNE RESPONSE and the dose of the vaccine administered.
Substances elaborated by viruses that have antigenic activity.
A highly contagious infectious disease caused by MORBILLIVIRUS, common among children but also seen in the nonimmune of any age, in which the virus enters the respiratory tract via droplet nuclei and multiplies in the epithelial cells, spreading throughout the MONONUCLEAR PHAGOCYTE SYSTEM.
Vaccines for the prevention of diseases caused by various species of Rickettsia.
An acute, highly contagious, often fatal infectious disease caused by an orthopoxvirus characterized by a biphasic febrile course and distinctive progressive skin eruptions. Vaccination has succeeded in eradicating smallpox worldwide. (Dorland, 28th ed)
Nonsusceptibility to the pathogenic effects of foreign microorganisms or antigenic substances as a result of antibody secretions of the mucous membranes. Mucosal epithelia in the gastrointestinal, respiratory, and reproductive tracts produce a form of IgA (IMMUNOGLOBULIN A, SECRETORY) that serves to protect these ports of entry into the body.
Vaccines or candidate vaccines used to prevent infection with parainfluenza viruses in humans and animals.
Antigenic determinants recognized and bound by the T-cell receptor. Epitopes recognized by the T-cell receptor are often located in the inner, unexposed side of the antigen, and become accessible to the T-cell receptors after proteolytic processing of the antigen.
The type species of ORTHOPOXVIRUS, related to COWPOX VIRUS, but whose true origin is unknown. It has been used as a live vaccine against SMALLPOX. It is also used as a vector for inserting foreign DNA into animals. Rabbitpox virus is a subspecies of VACCINIA VIRUS.
Proteins prepared by recombinant DNA technology.
Membrane glycoproteins from influenza viruses which are involved in hemagglutination, virus attachment, and envelope fusion. Fourteen distinct subtypes of HA glycoproteins and nine of NA glycoproteins have been identified from INFLUENZA A VIRUS; no subtypes have been identified for Influenza B or Influenza C viruses.
A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans.
A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 5 and neuraminidase 1. The H5N1 subtype, frequently referred to as the bird flu virus, is endemic in wild birds and very contagious among both domestic (POULTRY) and wild birds. It does not usually infect humans, but some cases have been reported.
A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 3 and neuraminidase 2. The H3N2 subtype was responsible for the Hong Kong flu pandemic of 1968.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
Proteins found in any species of protozoan.
Elements of limited time intervals, contributing to particular results or situations.
Species of the genus INFLUENZAVIRUS B that cause HUMAN INFLUENZA and other diseases primarily in humans. Antigenic variation is less extensive than in type A viruses (INFLUENZA A VIRUS) and consequently there is no basis for distinct subtypes or variants. Epidemics are less likely than with INFLUENZA A VIRUS and there have been no pandemics. Previously only found in humans, Influenza B virus has been isolated from seals which may constitute the animal reservoir from which humans are exposed.
Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice.
Vaccines or candidate vaccines used to prevent PSEUDORABIES (Aujeszky's disease), a herpesvirus of swine and other animals.
A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.
The type species of the genus INFLUENZAVIRUS A that causes influenza and other diseases in humans and animals. Antigenic variation occurs frequently between strains, allowing classification into subtypes and variants. Transmission is usually by aerosol (human and most non-aquatic hosts) or waterborne (ducks). Infected birds shed the virus in their saliva, nasal secretions, and feces.
Proteins found in any species of bacterium.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Virus diseases caused by the ORTHOMYXOVIRIDAE.
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)
The process of keeping pharmaceutical products in an appropriate location.
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
Acute VIRAL CNS INFECTION affecting mammals, including humans. It is caused by RABIES VIRUS and usually spread by contamination with virus-laden saliva of bites inflicted by rabid animals. Important animal vectors include the dog, cat, bat, fox, raccoon, skunk, and wolf.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
Extrachromosomal, usually CIRCULAR DNA molecules that are self-replicating and transferable from one organism to another. They are found in a variety of bacterial, archaeal, fungal, algal, and plant species. They are used in GENETIC ENGINEERING as CLONING VECTORS.
Layers of protein which surround the capsid in animal viruses with tubular nucleocapsids. The envelope consists of an inner layer of lipids and virus specified proteins also called membrane or matrix proteins. The outer layer consists of one or more types of morphological subunits called peplomers which project from the viral envelope; this layer always consists of glycoproteins.
A type of H. influenzae isolated most frequently from biotype I. Prior to vaccine availability, it was a leading cause of childhood meningitis.
Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).
Directed modification of the gene complement of a living organism by such techniques as altering the DNA, substituting genetic material by means of a virus, transplanting whole nuclei, transplanting cell hybrids, etc.
Infections with bacteria of the species NEISSERIA MENINGITIDIS.
Vaccines used in conjunction with diagnostic tests to differentiate vaccinated animals from carrier animals. Marker vaccines can be either a subunit or a gene-deleted vaccine.
Process of determining and distinguishing species of bacteria or viruses based on antigens they share.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
Peptides composed of between two and twelve amino acids.
Antigenic determinants recognized and bound by the B-cell receptor. Epitopes recognized by the B-cell receptor are located on the surface of the antigen.
The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis.
The giving of drugs, chemicals, or other substances by mouth.
Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
Vaccines or candidate vaccines used to prevent or treat PSEUDOMONAS INFECTIONS.
The type species of the FLAVIVIRUS genus. Principal vector transmission to humans is by AEDES spp. mosquitoes.
Sudden increase in the incidence of a disease. The concept includes EPIDEMICS and PANDEMICS.
Strains of Neisseria meningitidis which are the most common ones causing infections or disease in infants. Serogroup B strains are isolated most frequently in sporadic cases, and are less common in outbreaks and epidemics.
Antibodies reactive with HIV ANTIGENS.
The non-susceptibility to infection of a large group of individuals in a population. A variety of factors can be responsible for herd immunity and this gives rise to the different definitions used in the literature. Most commonly, herd immunity refers to the case when, if most of the population is immune, infection of a single individual will not cause an epidemic. Also, in such immunized populations, susceptible individuals are not likely to become infected. Herd immunity can also refer to the case when unprotected individuals fail to contract a disease because the infecting organism has been banished from the population.
Vaccines or candidate vaccines used to prevent LYME DISEASE.
An acute infectious disease caused by RUBULAVIRUS, spread by direct contact, airborne droplet nuclei, fomites contaminated by infectious saliva, and perhaps urine, and usually seen in children under the age of 15, although adults may also be affected. (From Dorland, 28th ed)
A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics.
Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.
Proteins isolated from the outer membrane of Gram-negative bacteria.
A disease caused by tetanospasmin, a powerful protein toxin produced by CLOSTRIDIUM TETANI. Tetanus usually occurs after an acute injury, such as a puncture wound or laceration. Generalized tetanus, the most common form, is characterized by tetanic muscular contractions and hyperreflexia. Localized tetanus presents itself as a mild condition with manifestations restricted to muscles near the wound. It may progress to the generalized form.
The expelling of virus particles from the body. Important routes include the respiratory tract, genital tract, and intestinal tract. Virus shedding is an important means of vertical transmission (INFECTIOUS DISEASE TRANSMISSION, VERTICAL).
Epidemics of infectious disease that have spread to many countries, often more than one continent, and usually affecting a large number of people.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
Antibodies to the HEPATITIS B ANTIGENS, including antibodies to the surface (Australia) and core of the Dane particle and those to the "e" antigens.
A species of CERCOPITHECUS containing three subspecies: C. tantalus, C. pygerythrus, and C. sabeus. They are found in the forests and savannah of Africa. The African green monkey (C. pygerythrus) is the natural host of SIMIAN IMMUNODEFICIENCY VIRUS and is used in AIDS research.
A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc.
A fulminant infection of the meninges and subarachnoid fluid by the bacterium NEISSERIA MENINGITIDIS, producing diffuse inflammation and peri-meningeal venous thromboses. Clinical manifestations include FEVER, nuchal rigidity, SEIZURES, severe HEADACHE, petechial rash, stupor, focal neurologic deficits, HYDROCEPHALUS, and COMA. The organism is usually transmitted via nasopharyngeal secretions and is a leading cause of meningitis in children and young adults. Organisms from Neisseria meningitidis serogroups A, B, C, Y, and W-135 have been reported to cause meningitis. (From Adams et al., Principles of Neurology, 6th ed, pp689-701; Curr Opin Pediatr 1998 Feb;10(1):13-8)
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
The altered state of immunologic responsiveness resulting from initial contact with antigen, which enables the individual to produce antibodies more rapidly and in greater quantity in response to secondary antigenic stimulus.
A CELL LINE derived from the kidney of the African green (vervet) monkey, (CERCOPITHECUS AETHIOPS) used primarily in virus replication studies and plaque assays.
Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.
A method of detection of the number of cells in a sample secreting a specific molecule. With this method, a population of cells are plated over top of the immunosorbent substrate that captures the secreted molecules.
A species of gram-negative, aerobic bacteria that is the causative agent of WHOOPING COUGH. Its cells are minute coccobacilli that are surrounded by a slime sheath.
A localized infection of mucous membranes or skin caused by toxigenic strains of CORYNEBACTERIUM DIPHTHERIAE. It is characterized by the presence of a pseudomembrane at the site of infection. DIPHTHERIA TOXIN, produced by C. diphtheriae, can cause myocarditis, polyneuritis, and other systemic toxic effects.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
Antibodies produced by a single clone of cells.
Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.
The type species of LYSSAVIRUS causing rabies in humans and other animals. Transmission is mostly by animal bites through saliva. The virus is neurotropic multiplying in neurons and myotubes of vertebrates.
The rate dynamics in chemical or physical systems.
Techniques where DNA is delivered directly into organelles at high speed using projectiles coated with nucleic acid, shot from a helium-powered gun (gene gun). One of these techniques involves immunization by DNA VACCINES, which delivers DNA-coated gold beads to the epidermis.
A genus of REOVIRIDAE, causing acute gastroenteritis in BIRDS and MAMMALS, including humans. Transmission is horizontal and by environmental contamination. Seven species (Rotaviruses A thru G) are recognized.
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
Viruses containing two or more pieces of nucleic acid (segmented genome) from different parents. Such viruses are produced in cells coinfected with different strains of a given virus.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds.
Resistance to a disease agent resulting from the production of specific antibodies by the host, either after exposure to the disease or after vaccination.
The degree of pathogenicity within a group or species of microorganisms or viruses as indicated by case fatality rates and/or the ability of the organism to invade the tissues of the host. The pathogenic capacity of an organism is determined by its VIRULENCE FACTORS.
The application of scientific knowledge or technology to pharmacy and the pharmaceutical industry. It includes methods, techniques, and instrumentation in the manufacture, preparation, compounding, dispensing, packaging, and storing of drugs and other preparations used in diagnostic and determinative procedures, and in the treatment of patients.
Proteins found in any species of virus.

Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. (1/2809)

A hybrid protein [Met-Ala-(His)6OprF190-342-OprI21-83] consisting of the mature outer membrane protein I (OprI) and amino acids 190 to 342 of OprF of Pseudomonas aeruginosa was expressed in Escherichia coli and purified by Ni2+ chelate-affinity chromatography. After safety and pyrogenicity evaluations in animals, four groups of eight adult human volunteers were vaccinated intramuscularly three times at 4-week intervals and revaccinated 6 months later with either 500, 100, 50, or 20 microg of OprF-OprI adsorbed onto A1(OH)3. All vaccinations were well tolerated. After the first vaccination, a significant rise of antibody titers against P. aeruginosa OprF and OprI was measured in volunteers receiving the 100- or the 500-microg dose. After the second vaccination, significant antibody titers were measured for all groups. Elevated antibody titers against OprF and OprI could still be measured 6 months after the third vaccination. The capacity of the elicited antibodies to promote complement binding and opsonization could be demonstrated by a C1q-binding assay and by the in vitro opsonophagocytic uptake of P. aeruginosa bacteria. These data support the continued development of an OprF-OprI vaccine for use in humans.  (+info)

Surface expression of a protective recombinant pertussis toxin S1 subunit fragment in Streptococcus gordonii. (2/2809)

In this study, the expression of the Bordetella pertussis S1 subunit was tested in Streptococcus gordonii, a commensal oral bacterium which has the potential to be a live oral vaccine vehicle. The DNA fragment encoding the N-terminal 179 amino acids of the S1 subunit was ligated into the middle part of spaP, the surface protein antigen P1 gene originating from Streptococcus mutans. The resulting construct, carried on the Escherichia coli-Streptococcus shuttle vector pDL276, was introduced into S. gordonii DL-1 by natural transformation. One of the transformants (RJMIII) produced a 187-kDa protein (the predicted size of the SpaP-S1 fusion protein) which was recognized by both the anti-pertussis toxin (anti-PT) and anti-SpaP antibodies, suggesting that an in-frame fusion had been made. Results from immunogold-electron microscopic studies and cellular fractionation studies showed that the fusion protein was surface localized and was mainly associated with the cell wall of RJMIII, indicating that SpaP was able to direct the fusion protein to the cell surface. A rabbit antiserum raised against heat-killed S. gordonii RJMIII recognized the native S1 subunit of PT in Western blotting and showed a weak neutralization titer to PT by the Chinese hamster ovary cell-clustering assay. BALB/c mice immunized with the heat-killed S. gordonii RJMIII were protected from the toxic effect of PT in the leukocytosis-promoting and histamine sensitization assays. In conclusion, a fragment of the S1 subunit of PT was successfully surface expressed in S. gordonii; the recombinant S1 fragment was found to be immunogenic and could induce protection against the toxic effect of PT in mice.  (+info)

Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and nonencapsulated Yersinia pestis. (3/2809)

To evaluate the role of Yersinia outer proteins (Yops) in conferring protective immunity against plague, six yop loci from Yersinia pestis were individually amplified by PCR, cloned, and expressed in Escherichia coli. The recombinant proteins were purified and injected into mice. Most Yop-vaccinated animals succumbed to infection with either wild-type encapsulated Y. pestis or a virulent, nonencapsulated isogenic variant. Vaccination with YpkA significantly prolonged mean survival time but did not increase overall survival of mice infected with the nonencapsulated strain. The only significant protection against death was observed in YopD-vaccinated mice challenged with the nonencapsulated strain.  (+info)

Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls. (4/2809)

The proliferative responses to a series of peptides constituting the human immunodeficiency virus type 1 (HIV-1) gp120 sequence were evaluated in 19 HIV-1-infected rgp160 vaccine recipients, 17 HIV-1-infected rgp120 vaccine recipients, 15 HIV-1-infected placebo recipients, and 18 HIV-1-uninfected controls. Many regions of the gp120 molecule were found to contribute proliferative epitopes, although there were clearly regions of relative dominance and silence. Vaccine recipients tended to have broader, more robust, and more frequent peptide recognition than the placebo recipients. Despite the considerable variability in the pattern of peptide recognition among individuals, there was a striking similarity between the rgp160 and rgp120 vaccinee groups as a whole. Low-risk HIV-1-uninfected individuals may react to a few peptides within the gp120 sequence as well, despite a lack of significant response to the whole gp120 protein.  (+info)

DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against seoul virus infection. (5/2809)

Seoul virus (SEOV) is one of four known hantaviruses causing hemorrhagic fever with renal syndrome (HFRS). Candidate naked DNA vaccines for HFRS were constructed by subcloning cDNA representing the medium (M; encoding the G1 and G2 glycoproteins) or small (S; encoding the nucleocapsid protein) genome segment of SEOV into the DNA expression vector pWRG7077. We vaccinated BALB/c mice with three doses of the M or S DNA vaccine at 4-week intervals by either gene gun inoculation of the epidermis or needle inoculation into the gastrocnemius muscle. Both routes of vaccination resulted in antibody responses as measured by ELISA; however, gene gun inoculation elicited a higher frequency of seroconversion and higher levels of antibodies in individual mice. We vaccinated Syrian hamsters with the M or S construct using the gene gun and found hantavirus-specific antibodies in five of five and four of five hamsters, respectively. Animals vaccinated with the M construct developed a neutralizing antibody response that was greatly enhanced in the presence of guinea pig complement. Immunized hamsters were challenged with SEOV and, after 28 days, were monitored for evidence of infection. Hamsters vaccinated with M were protected from infection, but hamsters vaccinated with S were not protected.  (+info)

Induction of a protective antibody response to foot and mouth disease virus in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1. (6/2809)

The utilization of transgenic plants expressing recombinant antigens to be used in the formulation of experimental immunogens has been recently communicated. We report here the development of transgenic plants of alfalfa expressing the structural protein VP1 of foot and mouth disease virus (FMDV). The presence of the transgenes in the plants was confirmed by PCR and their specific transcription was demonstrated by RT-PCR. Mice parenterally immunized using leaf extracts or receiving in their diet freshly harvested leaves from the transgenic plants developed a virus-specific immune response. Animals immunized by either method elicited a specific antibody response to a synthetic peptide representing amino acid residues 135-160 of VP1, to the structural protein VP1, and to intact FMDV particles. Additionally, the immunized mice were protected against experimental challenge with the virus. We believe this is the first report demonstrating the induction of a protective systemic antibody response in animals fed transgenic plants expressing a viral antigen. These results support the feasibility of producing edible vaccines in transgenic forage plants, such as alfalfa, commonly used in the diet of domestic animals even for those antigens for which a systemic immune response is required.  (+info)

A case-control study of risk factors for Haemophilus influenzae type B disease in Navajo children. (7/2809)

To understand the potential risk factors and protective factors for invasive Haemophilus influenzae type b (Hib) disease, we conducted a case-control study among Navajo children less than two years of age resident on the Navajo Nation. We analyzed household interview data for 60 cases that occurred between August 1988 and February 1991, and for 116 controls matched by age, gender, and geographic location. The Hib vaccine recipients were excluded from the analyses. Conditional logistic regression models were fit to examine many variables relating to social and environmental conditions. Risk factors determined to be important were never breast fed (odds ratio [OR] = 3.55, 95% confidence interval [CI] = 1.52, 8.26), shared care with more than one child less than two years of age (OR = 2.32, 95% CI = 0.91, 5.96); wood heating (OR = 2.14, 95% CI = 0.91, 5.05); rodents in the home (OR = 8.18, 95% CI = 0.83, 80.7); and any livestock near the home (OR = 2.18, 95% CI = 0.94, 5.04).  (+info)

Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines. (8/2809)

We previously reported that immunization with recombinant simian immunodeficiency virus SIVmne envelope (gp160) vaccines protected macaques against intravenous challenge by the cloned homologous virus E11S but that this protection was only partially effective against the uncloned virus, SIVmne. In the present study, we examine the protective efficacy of this immunization regimen against infection by a mucosal route. We found that the same gp160-based vaccines were highly effective against intrarectal infection not only with the E11S clone but also with the uncloned SIVmne. Protection against mucosal infection is therefore achievable by parenteral immunization with recombinant envelope vaccines. Protection appears to correlate with high levels of SIV-specific antibodies and, in animals protected against the uncloned virus, the presence of serum-neutralizing activities. To understand the basis for the differential efficacies against the uncloned virus by the intravenous versus the intrarectal routes, we examined viral sequences recovered from the peripheral blood mononuclear cells of animals early after infection by both routes. We previously showed that the majority (85%) of the uncloned SIVmne challenge stock contained V1 sequences homologous to the molecular clone from which the vaccines were made (E11S type), with the remainder (15%) containing multiple conserved changes (the variant types). In contrast to intravenously infected animals, from which either E11S-type or the variant type V1 sequences could be recovered in significant proportions, animals infected intrarectally had predominantly E11S-type sequences. Preferential transmission or amplification of the E11S-type viruses may therefore account in part for the enhanced efficacy of the recombinant gp160 vaccines against the uncloned virus challenge by the intrarectal route compared with the intravenous route.  (+info)

Synthetic Vaccines: Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
Selecta Biosciences Inc., a clinical stage biotechnology company that is developing an innovative class of targeted antigen-specific immune therapies with synthetic vaccine particles (SVPs), recently announced that SVP may be crucial to developing an innovative vaccine technology targeting mucosal tissues.
How to Cite: RAMASAMY, R., (1994). PROTECTIVE ANTIGENS, IMMUNE MECHANISMS AND SYNTHETIC VACCINES IN MALARIA-1994. Journal of the National Science Foundation of Sri Lanka. 22(2), pp.93-114. DOI: ...
According to the latest market report published by Credence Research, Inc. Recombinant Vaccines Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025 the global recombinant vaccines market is expanding at a CAGR of 6.4% from 2017 to 2025.. Browse the full report Recombinant Vaccines Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025 report at Market Insights. Recombinant vaccines are third generation vaccines, produced by using genetic engineering or recombinant DNA technology. It is expected that the global recombinant vaccines market will demonstrate lucrative market growth during the forecast period as these vaccines are more advanced as against the conventional alternatives. Expected launch of recombinant vaccines such as VPM1002 (BCG), EBOV-GP (ebola), Shingrix (herpes zoster), GSK-2189242A (pneumococcal infections), ID-93 (tuberculosis), PROSTVAC-VF etc. (prostate cancer) would ...
According to the latest market report published by Credence Research, Inc. Recombinant Vaccines Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025 the global recombinant vaccines market is expanding at a CAGR of 6.4% from 2017 to 2025.. Browse the full report Recombinant Vaccines Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025 report at Market Insights. Recombinant vaccines are third generation vaccines, produced by using genetic engineering or recombinant DNA technology. It is expected that the global recombinant vaccines market will demonstrate lucrative market growth during the forecast period as these vaccines are more advanced as against the conventional alternatives. Expected launch of recombinant vaccines such as VPM1002 (BCG), EBOV-GP (ebola), Shingrix (herpes zoster), GSK-2189242A (pneumococcal infections), ID-93 (tuberculosis), PROSTVAC-VF etc. (prostate cancer) would ...
Author: Seeberger, Peter H. et al.; Genre: Patent; Published online: 2015-03-11; Open Access; Title: Synthetic vaccines against Streptococcus pneumoniae
Recombinant Vaccines Market Analysis 2021:. The global Recombinant Vaccines Market is projected to rise remarkably on account of the increasing number of chronic and acute diseases and the advent of technologically advanced procedures to diagnose them. Recombinant Vaccines is an imaging scanner intensifier used for intraoperative imaging in surgical, orthopaedic, or emergency diagnostic procedures owing to its radiographic abilities.. The increasing number of chronic and acute diseases requiring imaging procedures is a crucial factor propelling the Recombinant Vaccines market growth. This, coupled with a rise in the demand for minimally invasive procedures, is also expected to aid in the expansion of the market. Also, the advent of artificial intelligence in radiology for assisting the discovery of genomic markers will boost the market growth in the coming years.. On the contrary, factors such as high cost of Recombinant Vaccines instruments may pose a significant hindrance to the market in the ...
Recombinant Vaccines Market. Recombinant vaccines are produced by using recombinant DNA technology or genetic engineering for the prevention of lethal diseases in human beings and animals. Recombinant vaccine is a biological preparation that provides active acquired immunity against a certain disease. Whereas individual being vaccinated produces antibodies against the protein antigen that protect a person from contracting the disease upon attack from the pathogenic microorganism. These vaccines functions on the immune response for diseases and to have preventive measures against diseases caused by various bacteria, and virus. These vaccines are much more advanced and effective as compare to conventional vaccines in the prevention of diseases such as malaria, typhoid, and human papillomavirus (HPV). Furthermore, Europe dominates the animal recombinant vaccines market as compared to other regions due to highly organized livestock and major demand for livestock products in Europe.. Request a sample ...
This is a parallel group prevention study. Participants from 2 age groups (adults 18 through 49 years of age and adults 50 years of age and older) will receive either 1 injection (Cohort 1) or 2 injections (Cohort 2) of study vaccine or placebo control.. As a precautionary step, a sentinel safety cohort of 6 participants (younger adults only) within each dosing group from Cohort 1 will be enrolled. An early safety data review will be performed, including evaluation of safety data and laboratory measures to Day 9. Upon acceptable safety demonstrated from unblinded data review by limited members of the Sponsor Study Team, the remaining participants will be enrolled simultaneously. ...
The prognosis of esophageal cancer is improved with the improvement of surgery, chemotherapy and radiation therapy. However, there are no standard therapies established for recurrent esophageal cancer. NY-ESO-1 antigen is expressed in 33% of patients. NY-ESO-1 protein is applicable without limitation by HLA types, and injected as a complex with cholesteryl pullulan (CHP), forming nano-particles (IMF-001), it can activate both CD4+ and CD8+ T cells. In this phase 1 study, the safety and the biological recommended dose will be determined ...
A new vaccine strategy could make flu shots cheaper, safer, and easier to produce. Using synthetic messenger RNA (mRNA) instead of proteins purified from viruses, German scientists have shown they can protect mice, ferrets, and pigs against influenza. This is a very interesting new approach, says Hans-Dieter Klenk, a virologist at the University of Marburg in Germany who was not involved in the work. Now, most flu vaccines consist of hemagglutinin and neuraminidase, the two proteins covering the surface of the virus. To produce these molecules, the three predominant influenza strains are cultured in fertilized chicken eggs or, increasingly, in cell culture. Virus is then harvested and broken up so that the two proteins can be purified ...
Inquire for Synthetic Peptide Vaccine Market 2017 Competitive Analysis, Trends and Forecast till 2022, with free sample copy of the report.
Global Synthetic Peptide Vaccine Sales Market Report 2017 includes market share, market research report, market trade, market prices, market geography trend and market forecast
Thanks to the reader who sent the link to a news story about this Nature Biotechnology report: Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. The abstract: Despite substantial improvements, influenza vaccine production-and availability-remain...
Selecta Biosciences, Inc., and JDRF, announced today that they have extended their joint research collaboration and attracted Sanofi as a partner for
Extensions of the folding problem have become particularly important in the last ten years or so because of interest in such possibilities as the preparation of totally synthetic vaccines. Can one look at the structure of a protein, preferably in three dimensions, and select areas on the surface which might be expected to have a strong tendency to fold properly even when chopped out of the total structure? I will describe to you a few experiments relating to this biological problem in a few moments. My own interest began with some work that was carried out with Ruth Arnon and Michael Sela at the Weizmann Institute on the so-called lysozyme loop -- a small disulphide-stabilized extension on the enzyme. When this loop was prepared synthetically and attached to a non-immunogenic carrier, injection into animals produced antibodies which did indeed recognize the parent enzyme molecule. One might say that this material constituted a synthetic vaccine against the lysozyme molecule. Through the activity ...
People who have repeated, unprotected exposure to HIV - yet remain uninfected - have a unique immune response that could serve as a model for protective vaccines, virologist Dr. Jay Levy reported at the 10th National AIDS Update Conference in San Francisco. Anti-viral drugs such as AZT and protease inhibitors do not prevent infection - and are unlikely to ever eradicate the virus from the body, asserted Levy. A synthetic vaccine that contains parts of the AIDS virus could trick the immune system into creating the right kind of response. Levys national study of the sex partners of infected people found, remarkably, that some individuals stay uninfected despite repeated episodes of unsafe sex. In studying patients blood in the laboratory, Levy found that if he attempted to create an infection in the presence of CD8 cells, viral replication was stopped.
The immunomodulating ability of adjuvants has been shown to enhance immune responses directed both specifically and non-specifically against tumor development and growth and to increase immune...
Acadia Pharmaceuticals Inc. announced it is hosting a conference call and webcast to discuss its top-line results from its Phase III trial with pimavanserin in patients with Parkinsons disease psychosis, and Inovio Pharmaceuticals Inc. announced that testing of multiple synthetic vaccine constructs for cytomegalovirus induced robust T cells in mice, according to company announcements, SEC filings and Bloomberg News.
Enhancement of Antituberculosis Immunity in a Humanized Model System by a Novel Virus-Vectored Respiratory Mucosal Vaccine Academic Article ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Recombinant subunit vaccines are some of the safest and most effective vaccines available, but their high cost and the requirement of advanced medical infrastructure for administration make them impractical for many developing world diseases. Plant-based vaccines have shifted that paradigm by paving the way for recombinant vaccine production at agricultural scale using an edible host. However, enthusiasm for
Background. We report the first-in-human safety and immunogenicity assessment of a prototype Ad26 vector-based human immunodeficiency virus (HIV) vaccine in humans. Methods. Sixty Ad26-seronegative, healthy, HIV-uninfected subjects were enrolled in a randomized, double-blinded, placebo-controlled, dose-escalation phase 1 study. Five groups of 12 subjects received 10(9)-10(11) vp of the Ad26-EnvA vaccine (N = 10/group) or placebo (N = 2/group) at weeks 0 and 24 or weeks 0, 4, and 24. Safety and immunogenicity were assessed. Results. Self-limited reactogenicity was observed after the initial immunization at the highest (10(11) vp) dose. No product-related SAEs were observed. All subjects who received the Ad26-EnvA vaccine developed Ad26 NAb titers, EnvA-specific enzyme-linked immunosorbent assays (ELISA) titers, and EnvA-specific enzyme-linked immunospot assays (ELISPOT) responses. These responses persisted at week 52. At week 28 in the 10(9), 10(10), 10(11) vp 3-dose and the 10(10) and 5 × ...
Fierce Vaccines Profiles Novel Synthetic Cancer Vaccine Inovio Pharmaceuticals, Inc. (NYSE Amex INO), which is advancing synthetic vaccines to fight cancers and
In this study, we compared the immunological efficacy of the vaccine candidates in BALB/c mice in terms of the levels of humoral and cellular immune responses. The results show that the rabies virus vector-based vaccine can induce remarkably earlier antibody response and higher levels of cellular immunity than the GEM particles vector. However, the GEM particles vector-based vaccine candidate can ...
While still in its infancy, mammalian synthetic biology has a very wide range of potentially game-changing applications. These include development of novel biosensors and diagnostics, synthetic vaccines, cell therapies and for improved bioprocessing ...
Rathwell, D. C. K.; Parameswarappa, S. G.; Govindan, S.; Chakkumkal, A.; Pereira, C. L.; Seeberger, P. H.: Protein and peptide-free synthetic vaccines against streptococcus pneumoniae type 3. WO2015040140 (2012 ...
FLU-MAL VLP- Chimeric Influenza-VLP used as vaccine platform for presentation of foreign antigens : FP7-2013-Marie Curie Actions- International Inc ...
The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data regarding BNT162b1 in younger adults from trials in Germany and the United States, support the selection of BNT162b2 for adva …
Current work demonstrates use of modern in silico tools for predicting peptide-based vaccine candidates. Four out of twenty one showed good HSV-2 neutralization activity. Further investigation is needed to obtain effective anti-HSV protective vaccine candidates. Future directions of this work will be further optimization of epitope selection strategy and use of other search algorithms ...
The present invention provides methods and compositions for rapidly producing multivalent recombinant vaccines using filamentous fungal hete
Protective efficacy of different doses of Ag85B-TB10.4 in IC31®.In two independent experiments (A and B) groups of mice were vaccinated with three different do
The epidemic of HIV/AIDS is sweeping across the world. It is of great importance to figure out new ways to curb this disease. Epitope-based vaccine is one of these solutions. In this study, a chimeric gene was obtained by combination of a designed HIV-1 multi-epitope gene (MEG) and HIV-1 p24 gene. A recombinant plasmid pUTA2-MEGp24 was then constructed by inserting MEGp24 gene into the downstream of the promoter (ATI-P7.5x20) of fowlpox virus (FPV) transfer vector pUTA2. The recombinant plasmid and wild-type FPV 282E4 strain were then co-transfected into CEF cells and homologous recombination occurred. A recombinant virus expressing HIV-1 protein MEGp24 was screened by genome PCR and Western blot assay. Large scale preparation and purification of the recombinant fowlpox virus (rFPV) were then carried out. BALB/c mice were immunized intramuscularly with the rFPV for three times on day 0, 14 and 42. Mice were executed and sampled one week after the third inoculation. Anti-HIV-1 antibody in serum ...
The 2009 Army Posture Statement, cites a World Health Organization estimate of between 20 annd 50 percent of the worlds population being effected if a pandemic were to emerge. WHO forecasts it may be six to nine months before a vaccine for a pandemic virus strain becomes available. In a separate report on pandemic influenza, the WHO described several challenges to producing sufficient volumes of vaccine using current, egg based protein-production technology, including the likelihood that two doses per person could be required due to the absence of pre-existing immunity. In short, the potential for a pandemic exists and current technological limitations on defensive measures put the health and readiness of U.S. military forces at risk. A technological solution to increase the speed and adaptability of vaccine production is urgently needed to match the broad biological threat. DARPAs Blue Angel Program seeks to demonstrate a flexible and agile capability for the Department of Defence to ...
Global Synthetic Peptide Vaccine Sales Market Report 2017 is a market research report available at US $4000 for a Single User PDF License from RnR Market Research Reports Library.
Pneumococcal surface protein A (PspA), a cell-surface protein present on all strains of pneumococci, has been shown to elicit protective antibody responses in mice in the absence of capsular polysaccharide. Whereas PspA is polymorphic, considerable cross-reactivity and cross-protection have been demonstrated among PspA proteins of pneumococci exhibiting different capsular and PspA serotypes. A gene segment encoding the nonrepetitive variable NH2-terminal portion of PspA has been cloned into three distinct recombinant Bacille Calmette-Guérin (rBCG) vectors, allowing for expression of PspA as a cytoplasmic or secreted protein, or a chimeric exported membrane-associated lipoprotein. All rBCG-PspA strains elicited comparable anti-PspA ELISA titers, ranging from 10(4) to 10(5) (reciprocal titers) in both BALB/c and C3H/HeJ mice. However, protective responses were observed only in animals immunized with the rBCG-PspA vaccines expressing PspA as a secreted protein or chimeric exported lipoprotein. In ...
Live recombinant viral vectors based on adenoviruses and poxviruses are among the most promising platforms for development of new vaccines against diseases such as malaria, tuberculosis, and HIV-AIDS. Vaccines based on live viruses must remain infectious to be effective, so therefore need continuous refrigeration to maintain stability and viability, a requirement that can be costly and difficult, especially in developing countries. The sugars sucrose and trehalose are commonly used as stabilizing agents and cryoprotectants for biological products. Here, we have exploited the ability of these sugars to vitrify on desiccation to develop a thermostabilization technique for live viral vaccine vectors. By slowly drying vaccines suspended in solutions of these disaccharide stabilizers onto a filter-like support membrane at ambient temperature, an ultrathin glass is deposited on the fibers of the inert matrix. Immobilization of two recombinant vaccine vectors-E1/E3-deleted human adenovirus type 5 and modified
Synthesis and Vaccine Evaluation of the Tumor Associated Carbohydrate Antigen RM2 from Prostate Cancer : This thesis focuses on the synthesis and vaccine evaluation of the prostate tumor- associated carbohydrate antigen RM2. The author first presents the use of the [1+2+3] one-pot sequential strategy to successfully synthesise the RM2 antigen and its analogues as single stereoisomers in every glycosylation step, producing good yields and stereoselectivity. He then introduces the conjugation of the
AIDS Cooperative Adjuvant Groups conduct preclinical studies of adjuvants and vaccine-adjuvant combinations.. AIDS Vaccine Reagent Project provides large quantities of reagents for preclinical and clinical studies related to vaccines.. Antibody Serologic Project identifies and standardizes monoclonal antibodies to characterize specific components of HIV and SIV.. AVEG (AIDS Vaccine Evaluation Group) includes six centers conducting Phase I and II trials of potential HIV vaccines.. AVEU (AIDS Vaccine Evaluation Unit) is an individual clinical site in the AVEG.. Chimpanzee Unit is a site for the evaluation of HIV vaccine concepts and products in chimpanzees.. Cooperative Mucosal Immunology Group for Investigations on AIDS Vaccines examines ways to stimulate and evaluate mucosal immune responses to HIV and SIV infection and vaccines.. DSMB (Data and Safety Monitoring Board) is an independent committee associated with the AVEG that reviews data of trials in progress to ensure that no participant is ...
According to an announcement made by India-based Bharat Biotech last week, the company has been working on two candidates for the Zika vaccine for more than a year. The vaccines in development - one of which is an inactivated for the virus, while the other is a recombinant vaccine containing antigens from the surface of the virus - could put the company ahead of others in the search for a Zika vaccine.. The company claims that they are likely the first to apply for a patent for their Zikavac vaccine candidate, which has already begun pre-clinical animal trials. Like all potential vaccines against the Zika virus - currently in development by companies such as Inovio, Sanofi and now Takeda - it could be many years before the vaccine is approved for widespread use among those at risk.. Currently, our efforts are towards scale-up and characterization of the vaccine product, said a statement released by Bharat. Our interest in Zika virus, an obscure virus when we started the project a year ago, ...
A malaria vaccine is a public health priority. In order to produce an effective vaccine, a multi-stage approach targeting both the blood and the liver stage infection is desirable. The vaccine candidates also need to induce balanced immune responses including antibodies, CD4+ and CD8+ T cells. Protein-based subunit vaccines like RTS,S are able to induce strong antibody response but poor cellular reactivity. Adenoviral vectors have been effective inducing protective CD8+ T cell responses in several models including malaria; nonetheless this vaccine platform exhibits a limited induction of humoral immune responses. Two approaches have been used to improve the humoral immunogenicity of recombinant adenovirus vectors, the use of heterologous prime-boost regimens with recombinant proteins or the genetic modification of the hypervariable regions (HVR) of the capsid protein hexon to express B cell epitopes of interest. In this study, we describe the development of capsid modified Ad5 vectors that ...
Selecta Biosciences, Inc. is a biopharmaceutical company developing first-in-class synthetic nanoparticle vaccines using its proprietary targeted Synthetic Vaccine Particle (tSVP ) technology. The tSVP platform enables full-integration of the key vaccine components, antigens and adjuvants, for highly-effective targeting to immune cells to produce an optimal immune response. The tSVP vaccines mimics the structure of natural pathogens with regards to size, shape and the sequence of immunological information that it delivers to immune cells, thus harnessing the body s defense system to produce a robust immune response. The unique attributes of full-integration, targeting and natural structure conferred by the tSVP platform create synthetic nanoparticle vaccines that are engineered for unprecedented safety and efficacy. This novel approach enables expanded opportunities for tSVP vaccines, and the company is pursuing opportunities across a range of clinical applications, including infectious, ...
Conserved-element vaccines and methods for designing conserved-element vaccines - Embodiments of the present invention include conserved-element vaccines and methods for designing and producing conserved-element vaccines. A conserved-element vaccine (CEVac) is a recombinant and/or synthetic vaccine that incorporates only highly conserved epitopes from an observed set of pathogen variants. The conserved epitopes are identified computationally by aligning biopolymer sequences, such as concatenated polypeptide sequences that together represent a pathogen proteome, corresponding to an observed set of pathogen variants, and computationally selecting conserved subsequences according to a number of subsequence-selection criteria. These subsequence-selection criteria may include a minimum conserved-subsequence length, a threshold frequency of occurrence of a particular monomer at each conserved, single-monomer position within a conserved subsequence, a threshold combined occurrence for a set of ...
The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was …
Development of Recombinant Vaccine against A(H1N1) 2009 Influenza Based on Virus-like Nanoparticles Carrying the Extracellular Domain of M2 Protein
PubMed journal article: Development of a recombinant vaccine against infectious coryza in chickens. Download Prime PubMed App to iPhone, iPad, or Android
NaturalNews) Biologists know that the thymus gland shrinks rapidly after puberty, but they have been unable to explain why this important gland turns to fat so quickly as people age. New research suggests that most peoples thymuses are missing some very important food-based antioxidants. If given the right amount of antioxidants, including Vitamin C and the enzyme catalase, the thymus can age more gracefully, keeping the immune system young and strong.. Exercising the thymus and giving it the right nutritional components gives it the capability to fight off pathogens into old age. Instead of retraining the immune system using synthetic vaccine chemicals and lab-grown viruses, healthy people can exercise their internal organs against all pathogens. They can let their intelligent natural defenses within their own thymus gland go to work. Research shows that if the thymus is given the right food-based antioxidants, it can thrive, keeping peoples immune systems young and strong as they age.. ...
Repetitive injections of a synthetic peptide vaccine in combination with a strong adjuvant prevented spontaneous tumors and caused established tumors to regress in a mouse model of HER2/neu breast cancer
Fasséli Coulibaly of Monash University in Australia will design a vaccine platform based on protein crystals (MicroCubes) produced by insect viruses to produce new and more potent vaccines with increased stability, obviating the need for refrigerated storage. The crystal structure will be engineered to present multiple antigens that will then be tested for their ability to induce an effective immune response. In Phase I, a proof-of-concept study was performed to establish MicroCubes as a promising vaccine platform, focusing on production versatility, potential vaccine delivery routes, and efficacy for inducing an immune response in mice. In Phase II, they will investigate the broader potential of MicroCubes as a generic vaccine platform that can be used to deliver a wide range of antigens, and will use it to develop a candidate vaccine against HIV.. ...
Synthesis and Vaccine) appraises currently So the dimensione of a 3ann. Gebiet otherwise are from ten to thirty, or rather more Banne. Stendortfuhrer( Garrison Commander).
Cutting-edge stability of dry and liquid formulations in human and animal health. Expertise in inactivated, live attenuated and live virus vaccines.
This is not true!. I am also a breakspear patient. I am staying anonymous too, what difference does putting a name make really - if I was staff I could just as easily make one up! I very much doubt the staff would bother to come onto this website. They know what they do works, they dont need to try to justify it to anyone. Theyre fully booked at Breakspear every day, and the patients success stories speak for themselves… I however am concerned for those reading this and being put off from going to Breakspear, when it can offer the solution that they are looking for… My reason for staying anonymous is I will be explaining things, in my laymans terms, the way I understand things. If any of the staff read this and I had got any tiny details wrong, I wouldnt want to embarrass myself! But anyway, I digress!. The cocktails are not forever. Let me add to the previous anons exlanation as it seems that you are possibly a little misinformed! With each item you are tested for, you get an end ...
The coronavirus pandemic has set off an unprecedented global scramble for a vaccine. There are more than 100 potential vaccine candidates, according to the World Health Organization, but only eight have entered the crucial clinical trials stage. Four are in the United States and Europe, with the rest in China.
Oral vaccines which are intended for global use do not necessarily induce the same immune responses in all children worldwide. In fact, several vaccines often induce less frequent and lower mean antib
A new Zika vaccine candidate has the potential to protect against the virus with a single dose, according to a research team led by scientists from the Perelman School of Medicine at the University of Pennsylvania. As reported in Nature this week, preclinical tests showed promising immune responses in both mice and monkeys.
A randomized trial shows that a candidate HSV-2 vaccine had a favorable safety profile and led to reduced shedding and lesion rates in human participants.
Tumors present an unique challenge to the immune response, and it is difficult to develop therapies to focus the power of the immune system towards eliminating tumors. This solution details what we know about the challenges in.
Codon optimization has applications in designing synthetic genes and DNA vaccines. Several software packages are available ...
"Broadly Neutralizing Synthetic Cannabinoid Vaccines". JACS Au. 1 (1): 31-40. doi:10.1021/jacsau.0c00057. Carrera, M. Rocío A.; ... Janda and colleagues then showed that an active vaccine against the orexigenic hormone ghrelin can slow the rate of weight gain ... Douglas Quenqua (October 3, 2011). "An Addiction Vaccine, Tantalizingly Close". New York Times. Lin, Mingliang; Lee, Jinny ... Nielsen, John; Brenner, Sydney; Janda, Kim D. (October 1993). "Synthetic methods for the implementation of encoded ...
"Prepared Statement from J. Craig Venter, Ph.D., and the J. Craig Venter Institute and Synthetic Genomics Vaccines, Inc. on the ... vaccine will perform any better than existing seasonal vaccines or the A(H1N1)pdm09 vaccines [about 60% to 70% effectiveness], ... The CDC and vaccine manufacturers are developing a candidate virus to be used in vaccine manufacturing if there is widespread ... Dormitzer, Philip R. (2014). "Rapid Production of Synthetic Influenza Vaccines". Influenza Pathogenesis and Control - Volume II ...
Other drugs included antitoxins, a few biological vaccines, and a few synthetic drugs. In the 1930s antibiotics emerged: first ... vaccines, immunoglobulins, immunosuppressants, interferons, monoclonal antibodies For allergic disorders[edit]. anti-allergics ... Later chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole ... vaccines, blood products used therapeutically (such as IVIG), gene therapy, and cell therapy (for instance, stem cell therapies ...
These vaccines use only the capsid proteins of the virus. Hepatitis B vaccine is an example of this type of vaccine.[201] ... Synthetic viruses. Many viruses can be synthesised de novo ("from scratch") and the first synthetic virus was created in 2002.[ ... Yellow fever vaccines and international travelers. Expert Review of Vaccines. 2008;7(5):579-87. doi:10.1586/14760584.7.5.579. ... Smallpox vaccines for biodefense: need and feasibility. Expert Review of Vaccines. 2008;7(8):1225-37. doi:10.1586/14760584.7. ...
Synthetic vaccines are now being produced in the lab. These have caused a lot of excitement in the pharmaceutical industry as ... Collins, James (2012). "Synthetic Biology: Bits and pieces come to life". Nature. 483 (7387): S8-S10. Bibcode:2012Natur.483S... ... "First Self-Replicating Synthetic Bacterial Cell". J. Craig Venter Institute. Archived from the original on 2012-05-31. ... Scientist that favor the development of synthetic biology claim that the use of biosafety mechanisms such as suicide genes and ...
This software was used to design and develop synthetic vaccines. Snapshot DNA Phenotyping Service is the name of a DNA ... Parabon NanoLabs has developed oncology therapeutics and synthetic vaccines using nanotechnology and DNA phenotyping. Together ...
From New Antibiotics to Supramolecular Synthetic Vaccines". Accounts of Chemical Research. 50 (6): 1323-1331. doi:10.1021/acs. ... Fully synthetic cyclic peptide libraries of this peptidomimetic template produced compounds that had an antimicrobial activity ... "Sensitivity of periodontal pathogens to the bactericidal activity of synthetic protegrins, antibiotic peptides derived from ...
ISBN 978-1-84110-100-2. Gaidzik N, Westerlind U, Kunz H (May 2013). "The development of synthetic antitumour vaccines from ... Using MUC1, vaccines are being tested against a type of blood cancer called multiple myeloma. The technology could in theory be ... Nemunaitis J, Bedell C, Klucher K, Vo A, Whiting S (2013). "Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in ... for the MUC1 vaccine ONT-10, which has had a phase 1 clinical study. Cluster of differentiation List of histologic stains that ...
From New Antibiotics to Supramolecular Synthetic Vaccines". Accounts of Chemical Research. 50 (6): 1323−1331. doi:10.1021/acs. ... It is a synthetic cyclic beta hairpin peptidomimetic based on the cationic antimicrobial peptide protegrin I (PG-1) and the ... A fully synthetic cyclic peptide-like molecule containing a D-proline-L-proline template grafted into a peptidomimetic scaffold ...
... a synthetic peptide immunocontraceptive". Vaccine. 15: 1761-1766. doi:10.1016/s0264-410x(97)00105-9. Kurth, BE; L Digilio; P ... for the development of contraceptive vaccine for male". Vaccine. 26: 3711-3718. doi:10.1016/j.vaccine.2008.04.060. Wang, M; JL ... Repro-Bloc is GnRH vaccine marketed for use in domestic animals in general. Improvac® is a GnRH vaccine marketed for use in ... This has led to interest in developing hCG vaccines specifically for cancer treatment. The vaccine tested in the phase II ...
Wang Pengfei (March 2021). "Natural and Synthetic Saponins as Vaccine Adjuvants" Vaccines 9(3):222. PMID: 33807582 PMCID: ... "Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer". Expert Rev Vaccines. 10 (4): 463-70. doi:10.1586/erv ... QS-21 is a purified plant extract used as a vaccine adjuvant. It is derived from the soap bark tree (Quillaja saponaria), which ... It has been tested as an adjuvant in various vaccines in attempts to improve their efficacy. It is believed to enhance both ...
He is known for his work on semi-synthetic glycoconjugate vaccines. He has designed a breast cancer vaccine prototype. René Roy ... It is the first human semi-synthetic glycoconjugate vaccine approved and remains the only one. In use since 2004, more than 34 ... He is a pioneer in the development of synthetic glycoconjugate vaccines both for human and veterinary health, having co- ... developed the first and sole marketed semi-synthetic vaccine for human use, preventing bacterial meningitis and pneumonia in ...
In 1955, Salk's polio vaccine was made public. 1952 Einsteinium Einsteinium is a metallic synthetic element. On the periodic ... 1983 Pneumococcal polysaccharide vaccine Pneumococcal polysaccharide vaccine, also known as Pneumovax, is a vaccine used to ... Jonas Salk announced his discovery of a trial vaccine for Polio, or poliomyelitis. Salk's vaccine was composed of "killed" ... Seaborgium is a synthetic element whose most stable isotope 271Sg has a half-life of 1.9 minutes. Chemistry experiments with ...
Following World War II synthetic fertilizer use increased rapidly. The discovery of antibiotics and vaccines facilitated ... These technologies included "miracle seeds", pesticides, irrigation, and synthetic nitrogen fertilizer. In the 1970s, ... as critical factors in plant growth led to the manufacture of synthetic fertilizers, further increasing crop yields. In 1909, ...
The types of vaccines that would be used are synthetic peptide vaccines. Haddad, J.G.; Rouille, Y.; et al. (2017). " ... The hope for these vaccines is that they will be able to block the entry of Hepatitis C if they can block the formation of E1. ... Antiviral and Vaccine Targets". ACS Infectious Diseases. 2 (11): 749-762. doi:10.1021/acsinfecdis.6b00110. PMID 27933781. ... Antiviral and Vaccine Targets". ACS Infectious Diseases. 2 (11): 749-762. doi:10.1021/acsinfecdis.6b00110. PMID 27933781. ...
Manuel Elkin Patarroyo, Colombian pathologist who made the world's first attempt of synthetic vaccine for malaria. Recipient of ... "The yellow fever vaccine: A history"-section "First vaccine attempts". Yale J. Biol. Med. 83 (2): 77-85. PMC 2892770. PMID ...
TNX-801 is a new potential vaccine for smallpox. TNX-801 is a synthetic form of horsepox, which is an otherwise extinct virus. ... Evolutionary analysis of modern vaccines indicates that the vaccine isolated and used by Edward Jenner to vaccinate against ... "A century-old vaccine vial sheds light on one of medicine's enduring mysteries, STAT News, by Helen Branswell October 11, 2017 ... The finding that a horsepox vaccine was in clinical use in the U.S. in 1902 to protect against smallpox provides strong support ...
CS1 maint: discouraged parameter (link) "Company: Synthetic intra-cellular HIV vaccine". Retrieved 13 November 2017. CS1 maint ... I work on gene therapies (and vaccines) and I am a subject in my GHRH clinical trial". TReddit. Retrieved 20 Nov 2017. CS1 ... California to develop a gene therapy to treat HIV AIDS using a combination of GHRH and an intracellular vaccine. He has ...
Wang Pengfei (March 2021). "Natural and Synthetic Saponins as Vaccine Adjuvants" Vaccines 9(3):222. PMID: 33807582 PMCID: ... RTS,S is the most advanced vaccine for malaria in development. Agenus is the sole US-manufacturer of a patented and FDA- ... "Malaria Vaccine Study". Archived from the original on 2013-10-11. Retrieved 2013-10-12. VISWANATH, P. (April 29, 2021) "COVID- ... Because each cancer is unique, the vaccine is derived from the patient's own tumor sample. To process these samples, Agenus has ...
Megazol in a study seems more active against Chagas than benznidazole but has not been studied in humans.[76] A Chagas vaccine ... This is done by using sprays and paints containing insecticides (synthetic pyrethroids), and improving housing and sanitary ... There is currently no vaccine against Chagas disease.[29] Prevention is generally focused on decreasing the numbers of the ... A number of potential vaccines are currently being tested. Vaccination with Trypanosoma rangeli has produced positive results ...
Chemicals developed for use in World War II gave rise to synthetic pesticides. Developments in shipping networks and technology ... The discovery of antibiotics and vaccines facilitated raising livestock in larger numbers by reducing disease. ... hormones and vaccines; protein, mineral and vitamin supplements; frequent health inspections; biosecurity; and climate- ...
A Retrospective on Fully Synthetic Carbohydrate-Based Anticancer Vaccines". Angew. Chem. Int. Ed. 39: 836-863. doi:10.1002/( ... In 2006, he was awarded the Benjamin Franklin Medal in Chemistry for his achievements in synthetic organic chemistry, ... several other awards including the American Chemical Society's Guenther Award and Aldrich Award for Creative Work in Synthetic ...
Scientists at Vaccine and Immunotherapy Center at The Wistar Institute have designed and tested the first-of-its-kind synthetic ... "A novel synthetic DNA vaccine elicits protective immune responses against Powassan virus". PLOS Neglected Tropical Diseases. 14 ... No approved vaccine or antiviral drug exists. Prevention of tick bites is the best precaution. Powassan virus (POWV) is a ... There are currently no medications or approved vaccines to treat or prevent the POWV. People affected by Powassan virus ...
"Clinical and immunological effects of a synthetic beta-human chorionic gonadotropin vaccine". Int. J. Oncol. 5 (6): 1447-1454. ... Overall, the vaccines were tolerated well by the patients. 69% (55 of the 73 patients). After successfully completing a Phases ... Avicine, tested and developed by AVI BioPharma, and also known as CTP-37 was trialled as a possible cancer vaccine to treat a ... The vaccine operated by eliciting antibodies against human chorionic gonadotropin (hCG) a cancer associated protein expressed ...
"A novel synthetic DNA vaccine elicits protective immune responses against Powassan virus". PLOS Neglected Tropical Diseases. 14 ... combination vaccine. The Wistar-developed vaccine led the charge in the eradication of rubella, which was declared eradicated ... This vaccine, which was developed at Wistar in the 1960s and '70s, has helped to make rabies-related human death a rarity in ... Two rabies vaccines were developed at Wistar and are used worldwide to prevent rabies-related deaths in humans and wildlife. ...
An important field of application are mRNA vaccines, of which the first authorized for use in humans were COVID-19 vaccines to ... A nucleoside-modified messenger RNA (modRNA) is a synthetic messenger RNA (mRNA) in which some nucleosides are replaced by ... Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, Middelberg AP (January 2014). "Nanoparticle vaccines". Vaccine. 32 (3): 327- ... An important application is the development of mRNA vaccines, of which the first authorized were COVID-19 vaccines (such as ...
LUNAR-RPL is a project in collaboration with Synthetic Genomics to develop improved technology for vaccines and therapeutics. ... Vaccine medicines include a vaccine candidate for COVID-19, currently co-developed with Singaporean scientists at Duke-NUS ... The company has a portfolio of eight mRNA-based therapeutics and two mRNA-based vaccines in development. On June 27th 2019, the ... The company has programs in development for novel RNA therapeutics and mRNA vaccines, both wholly owned and in collaboration ...
The synthetic hard surface is being installed in the United States as well as in Israel. Health care workers may be exposed to ... Vaccines are available to provide some protection to workers in a healthcare setting. Depending on regulation, recommendation, ... CDC Vaccine Site Weinstein RA (September 1998). "Nosocomial infection update". Emerging Infectious Diseases. CDC. 4 (3): 416-20 ... Environmental Protection Agency has approved the registration of 355 different antimicrobial copper alloys and one synthetic ...
A synthetic vaccine can be safer than a traditional vaccine as there is no risk of accidentally releasing the virus, and does ... "Lighting up a new path for novel synthetic Polio vaccine - - Diamond Light Source". Retrieved 2020-04-26. ... "Scientists prove new approach to Polio vaccines works". ScienceDaily. Retrieved 2020-04-27. "New polio vaccine being developed ... She warned the public not to get too optimistic about a COVID-19 vaccine, as they can take "decades" to get to market. ...
A vaccine against inflammatory acne has shown promising results in mice and humans.[50][196] Some have voiced concerns about ... "Synthetic androgens as designer supplements". Current Neuropharmacology (Review). 13 (1): 89-100. doi:10.2174/ ... "In development: a vaccine for acne". New Scientist. Archived from the original on 2 April 2015. Retrieved 30 March 2015 ... creating a vaccine designed to neutralize a stable community of normal skin bacteria that is known to protect the skin from ...
Vaccines[edit]. Tomatoes (along with potatoes, bananas and other plants) are being investigated as vehicles for delivering ... Goyal, R.; Ramachandran, R.; Goyal, P.; Sharma, V. (2007). "Edible vaccines: Current status and future". Indian Journal of ... Korean scientists are looking at using the tomato to express a vaccine against Alzheimer's disease.[42] Hilary Koprowski, who ... led a group of researchers in developing a tomato expressing a recombinant vaccine to SARS.[43] ...
Ovandrotone albumin (Fecundin, Ovastim) and Androvax (androstenedione albumin) are immunogens and vaccines against ... Luthy IA, Begin DJ, Labrie F (1988). "Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive ... There are several classes of antiandrogens including (1) antigonadotropins (eg, LHRH agonists/antagonists, synthetic estrogens ...
"MMR Vaccine and Autism - CDC. (Measles, Mumps, and Rubella). FACT SHEET" (PDF). Retrieved 2011-11-26. "How Accurate ... and are more efficacious than their synthetic and animal derived counterparts. Until evidence is found to the contrary, ... Among them, his 2009 appearance on Fox News in regards to the H1N1 vaccine, in which Holtorf plainly states he "definitely ... Holtorf has also taken an unpopular stance that children are over vaccinated and that vaccines may be associated with autism. ...
Verma R, Khanna P «Development of Toxoplasma gondii vaccine: A global challenge» (en anglès). Hum Vaccin Immunother, 2013 Feb; ... Giovati L, Santinoli C, Mangia C, Vismarra A, et al «Novel Activity of a Synthetic Decapeptide Against Toxoplasma gondii ... Li ZY, Lu J, Zhang NZ, Chen J, Zhu XQ «Immune Responses Induced by HSP60 DNA Vaccine against Toxoplasma gondii Infection in ... Foroutan M, Zaki L, Ghaffarifar F «Recent progress in microneme-based vaccines development against Toxoplasma gondii» (en ...
Cuba vaccine deal breaks embargo, BBC, July 29, 1999 *^ William Ventres (February 2012). "Book Review: Caring for Them From ... A 2018 paper using a synthetic control method found that infant mortality increased in the first years of the Castro regime ... Cuba also successfully exports many medical products, such as vaccines.[63] Health tourism[edit]. Cuba attracts about 20,000[64 ... The Cuban vaccine is used throughout Latin America. After outbreaks of meningitis B in the United States, the U.S. Treasury ...
Vaccines - a Biography edited by Andrew W. Artenstein ISBN 978-1-4419-1107-0[page needed] ... Synthetic (recombinant or cell-clone) human immunoglobulins can now be made, and for several reasons (including the risk of ... Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine (Report). Centers for Disease ... Main articles: Smallpox vaccine and Edward Jenner. In 1796, Edward Jenner, a doctor and scientist who had practiced variolation ...
In 1985, the first human vaccine obtained by genetic engineering from animal cells, the vaccine against hepatitis B, was ... the first synthetic alpha-adrenoreceptor antagonist (Prosympal), the first antihistamine (Piperoxan), the first active drug on ... Chantemesse's typhoid vaccineEdit. During the summer of 1900, the extremely hot weather and scarcity of the water supply in ... Vaccines and Diagnostic ProductsEdit. Production and marketing of diagnostic tests developed in the Institute laboratories are ...
... caused a rapid change the development of vaccines, medical treatments and diagnostic methods. Some of these include synthetic ... Following on from this, in 1857 Louis Pasteur also designed vaccines against several diseases such as anthrax, fowl cholera and ... The same principles are used for developing vaccines today. ... recombinant DNA and the first genetically engineered vaccine ...
Other drugs included antitoxins, a few biological vaccines, and a few synthetic drugs. In the 1930s, antibiotics emerged: first ... vaccines, immunoglobulins, immunosuppressants, interferons, monoclonal antibodies For allergic disordersEdit. anti-allergics, ... Later chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole ... vaccines, blood products used therapeutically (such as IVIG), gene therapy, and cell therapy (for instance, stem cell therapies ...
... can also be effected using the tools of synthetic organic chemistry. Unlike the biochemical processes, synthetic ... Viral pathogenesis • Preventive and therapeutic vaccines. 11: 63-9. doi:10.1016/j.coviro.2015.02.002. PMC 4827424. PMID ... "Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design". Current Opinion in Virology ... "cis glycosylation as the driving force of progress in synthetic carbohydrate chemistry". Chemical Science. 6 (5): 2687-2704. ...
Some synthetic cannabinoids such as Nabilone (Cesamet) or the JWH series.. *Sativex is an oral spray containing THC and CBD. It ...
Clayton, E (2012). Adverse Effects of Vaccines: Evidence and Causality. Institute of Medicine. p. 65. ISBN 978-0-309-21435-3. . ... Other foods containing allergenic proteins include soy, wheat, fruits, vegetables, maize, spices, synthetic and natural colors, ... An Institute of Medicine report says that food proteins contained in vaccines, such as gelatin, milk, or egg can cause ... sensitization (development of allergy) in vaccine recipients, to those food items.[32] ...
... the bacterium to randomly change its characteristics into six alternative states that could pave the way to improved vaccines. ... Synthetic genetic array. References[edit]. *^ Dupont C, Armant DR, Brenner CA (September 2009). "Epigenetics: definition, ...
For example, synthetic peptides can be used as probes to see where protein-peptide interactions occur- see the page on Protein ... vaccine peptides , immune/inflammatory peptides, brain peptides, endocrine peptides, ingestive peptides, gastrointestinal ...
... herbal medicines and synthetic drugs may interact, causing toxicity to the patient. Herbal remedies can also be dangerously ... Anti-vaccine movement. *Vaccines causing autism. *GMO conspiracy theories. *HIV/AIDS origins ...
The approaches taken by governments to assess and manage the risks associated with the use of genetic engineering technology and the development and release of GMOs vary from country to country, with some of the most marked differences occurring between the United States and Europe. The U.S. regulatory policy is governed by the Coordinated Framework for Regulation of Biotechnology[48] The policy has three tenets: "(1) U.S. policy would focus on the product of genetic modification (GM) techniques, not the process itself, (2) only regulation grounded in verifiable scientific risks would be tolerated, and (3) GM products are on a continuum with existing products and, therefore, existing statutes are sufficient to review the products."[49] European Union by contrast enacted regulatory laws in 2003 that provided possibly the most stringent GMO regulations in the world.[5] All GMOs, along with irradiated food, are considered "new food" and subject to extensive, case-by-case, science-based food ...
Drugs that have been introduced for uses other than analgesics are also used in pain management. Both first-generation (such as amitriptyline) and newer anti-depressants (such as duloxetine) are used alongside NSAIDs and opioids for pain involving nerve damage and similar problems. Other agents directly potentiate the effects of analgesics, such as using hydroxyzine, promethazine, carisoprodol, or tripelennamine to increase the pain-killing ability of a given dose of opioid analgesic. Adjuvant analgesics, also called atypical analgesics, include nefopam, orphenadrine, pregabalin, gabapentin, cyclobenzaprine, hyoscine (scopolamine), and other drugs possessing anticonvulsant, anticholinergic, and/or antispasmodic properties, as well as many other drugs with CNS actions. These drugs are used along with analgesics to modulate and/or modify the action of opioids when used against pain, especially of neuropathic origin. Dextromethorphan has been noted to slow the development of tolerance to opioids ...
"Diamyd announces completion of type 1 diabetes vaccine trial with long term efficacy demonstrated at 30 months". Press Release ... Kaufman DL, Houser CR, Tobin AJ (February 1991). "Two forms of the gamma-aminobutyric acid synthetic enzyme glutamate ...
"Synthetic track at GMC Balayogi stadium will be protected:SAAP". The Hindu. 15 December 2005. Archived from the original on 5 ... Only 61% of children had been provided with all basic vaccines (BCG, measles and full courses of polio and DPT), fewer than in ...
"World's first Parkinson's vaccine is trialled". New Scientist. London. 7 June 2012. Archived from the original on 23 April 2015 ... The appearance of parkinsonism in a group of drug addicts in the early 1980s who consumed a contaminated batch of the synthetic ... A vaccine that primes the human immune system to destroy alpha-synuclein, PD01A (developed by Austrian company, Affiris), has ...
Figure 4](b) Examples of synthetic, pharmaceutically important substituted amphetamines.. *^ a b Glennon RA (2013). " ... Mephedrone is a synthetic stimulant drug of the amphetamine and cathinone classes. Slang names include drone[93] and MCAT.[94] ... Countless variation in functional group substitutions has yielded a collection of synthetic drugs with diverse pharmacological ... "Parents cautioned against over the counter synthetic speed". NBC 33 News. Archived from the original on 28 September 2011 ...
To cite one example, in 1978 Genentech developed synthetic humanized insulin by joining its gene with a plasmid vector inserted ... This branch involves the production of vaccines and antibiotics, regenerative therapies, creation of artificial organs and new ... The genetically engineered bacteria are able to produce large quantities of synthetic human insulin at relatively low cost.[36] ...
... the need for development of a new generation smallpox vaccine". Vaccine. 29 Suppl 4: D49-53. doi:10.1016/j.vaccine.2011.05.037 ... "Synthetic horsepox viruses and the continuing debate about dual use research". PLOS Pathogens. 14 (10): e1007025. doi:10.1371/ ... The vaccine is given using a bifurcated (two-pronged) needle that is dipped into the vaccine solution. The needle is used to ... doi:10.1016/j.vaccine.2011.02.081. PMID 21376120.. *^ "Century-old smallpox scabs in N.M. envelope". USA Today: Health and ...
Neutropenia (a decrease of the neutrophil granulocyte count below 0.5 x 109/litre) can be improved with synthetic G-CSF ( ... Taxanes are natural and semi-synthetic drugs. The first drug of their class, paclitaxel, was originally extracted from the ... semi-synthetic vinca alkaloids were produced: vinorelbine (used in the treatment of non-small-cell lung cancer[46][48][49]), ...
Liver: disruption of protein synthetic function manifests acutely as progressive disruption of blood clotting due to an ... "Anti-endotoxin vaccines: Back to the future". Virulence. 5 (1): 219-25. doi:10.4161/viru.25965. PMC 3916378. PMID 23974910 ...
Vaccine Research Center Information concerning vaccine research clinical trials for Emerging and re-Emerging Infectious ... "Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry. 23 (9): 2392. doi:10.3390/molecules23092392. ISSN ... Gerhard Domagk developed sulphonamides, the first broad spectrum synthetic antibacterial drugs. Medical specialists[edit]. The ... Edward Jenner, Jonas Salk and Albert Sabin developed effective vaccines for smallpox and polio, which would later result in the ...
... tumefaciens causes crown-gall disease in plants. The disease is characterised by a tumour-like growth or gall on the infected plant, often at the junction between the root and the shoot. Tumors are incited by the conjugative transfer of a DNA segment (T-DNA) from the bacterial tumour-inducing (Ti) plasmid. The closely related species, Agrobacterium rhizogenes, induces root tumors, and carries the distinct Ri (root-inducing) plasmid. Although the taxonomy of Agrobacterium is currently under revision it can be generalised that 3 biovars exist within the genus, Agrobacterium tumefaciens, Agrobacterium rhizogenes, and Agrobacterium vitis. Strains within Agrobacterium tumefaciens and Agrobacterium rhizogenes are known to be able to harbour either a Ti or Ri-plasmid, whilst strains of Agrobacterium vitis, generally restricted to grapevines, can harbour a Ti-plasmid. Non-Agrobacterium strains have been isolated from environmental samples which harbour a Ri-plasmid whilst laboratory ...
Vaccines have been developed that prevent infection by some carcinogenic viruses.[126] Human papillomavirus vaccine (Gardasil ... including both naturally occurring and synthetic asbestos-like fibers, such as wollastonite, attapulgite, glass wool and rock ... "Cancer Vaccine Fact Sheet". NCI. 8 June 2006. Retrieved 28 March 2018.. ... and Cervarix) decrease the risk of developing cervical cancer.[126] The hepatitis B vaccine prevents infection with hepatitis B ...
MacKenzie D։ «In development: a vaccine for acne»։ New Scientist։ Արխիվացված օրիգինալից 2 April 2015-ին։ Վերցված է 30 March ... Joseph JF, Parr MK (January 2015)։ «Synthetic androgens as designer supplements»։ Current Neuropharmacology (Review) 13 (1): 89 ...
... are now working on the first synthetic biology-derived animal vaccine. Traditionally, bacterial vaccines are made from simply ... Synthetic Vaccines. 18 Jan 2018 , 22:24 GMT. , Posted by Markus Schmidt , Category: Research ... E) Last but not least, once approved for farm animals, the next goal will be synthetic biology vaccines for human infections ... A) The market for animal products and animal vaccines is huge, with M. hyopneumoniae vaccines alone currently topping $150 ...
... Advanced genetic engineering is already changing vaccine development and ... Synthetic biology is breathing new life into the old-fashioned world of vaccine production, raising hopes that manufacturers ... could release vaccines much more quickly when outbreaks occur.. At a meeting on synthetic biology held at MIT, the drug company ... The synthetic viral genome combines a genomic backbone common to many flu viruses with genes specific to the strains seen in a ...
By using nanoparticle cases to ensure that vaccines produce the right immune response over the right time, science could cure ... Synthetic vaccines often manage to avoid some of the safety concerns associated with infecting the body with a live virus - but ... Synthetic Vaccine May Fight Malaria, HIV. By Janelle Weaver 2011-02-28T17:18:11Z. ... "We can use these to deliver any synthetic vaccine very effectively to immune cells," said James Moon, a postdoctoral researcher ...
In: Vaccines: new generation immunological adjvant / Gregoriadis, G., - p. 127 - 133.. Department(s). ID Lelystad, Institute ...
Recombinant protein expression is influenced by a variety of variables associated with the choice of codons used for synthetic ... Rotavirus and Norovirus vaccines and various proprietary expression elements. ...
These synthetic vaccines, in combination with Inovios proprietary electroporation delivery, have been shown in humans to ... Inovio Pharmaceuticals Synthetic Vaccines Delivered with Minimally Invasive Skin Electroporation Technology Generate Potent ... HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More ... Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent ...
Synthetic carriers have the ability to alter and direct the immune response, and a better control of particle properties will ... Synthetic carriers (also known as vectors) are usually particulate and have multiple properties, which can be varied to control ... Furthermore, the requirements for a synthetic carrier, such as size, charge, and surface chemistry are reviewed in order to ... comprehensively analyzes both historical and recent studies in which synthetic carriers are used to deliver malaria vaccines. ...
... has made significant advances in developing a vaccine for chlamydia using synthetic biology, sponsored by a two-year National ... Using synthetic biology for chlamydia vaccines. by Maren Hunsberger, Lawrence Livermore National Laboratory ... Davis and the vaccine group at Synthetic Genomics, Inc . Chlamydia is the most common infectious sexually transmitted disease, ... This document is subject to copyright. Apart from any fair ...
BioWorld Online is the news service of record for the biotechnology industry and is updated every business morning. BioWorld Online will keep you up to date on all of the industrys business, science and regulatory news -- mergers and collaborations, FDA hearings and results, breakthroughs in research and much more.
Scientists at The Wistar Institute have designed and tested the first-of-its-kind synthetic DNA vaccine against Powassan virus ... to design and test this synthetic DNA vaccine.. The effectiveness of this vaccine was evaluated in preclinical studies that ... First-of-its-kind synthetic DNA vaccine designed against Powassan virus. *Download PDF Copy ... Scientists at The Wistar Institute have designed and tested the first-of-its-kind synthetic DNA vaccine against Powassan virus ...
In spite of the immunogenic weakness previously attributed to epitope-based vaccines a synthetic vaccine containing a 17 amino ... On the other hand, synthetic vaccines based on immunogenic epitopes offer advantages over traditional vaccines since they are ... Therefore, the efficacy yield of a synthetic vaccine can be potentiated by using the proper combination of target epitopes. ... Traditional vaccines contain PAMPs and induce strong immune responses, while recombinant vaccines are less potent. ...
Microbial Immunity and Vaccines. Multiple Antigen Peptide Vaccines against Plasmodium falciparum Malaria Babita Mahajan, Jay A ... Microbial Immunity and Vaccines. Efficacy of Intracellular Activated Promoters for Generation of Salmonella-Based Vaccines Xin ... Microbial Immunity and Vaccines. Salmonella Vaccine Vectors Displaying Delayed Antigen Synthesis InVivo To Enhance ... Microbial Immunity and Vaccines. Protection against Intestinal Amebiasis by a Recombinant Vaccine Is Transferable by T Cells ...
Synthetic peptide compositions with immunoreactivities to antibodies to HTLV and as vaccines ... The synthetic reagent can than be used to detect the presence of antibodies to HTLV-I and/or HTLV-II in body fluids and ... Synthetic peptide and process of using same for the detection and diagnosis of AIDS and pre-AIDS conditions. 1988-04-05. Wang ... Performance of this synthetic peptide-based EIA (HTLV-II specific) is presented in Table IV. The results in Table IV show that ...
... Vaccine. 2002 Jun 21 ... might be an appropriate candidate when the synthetic recombinant vaccine approach is considered. ... Furthermore, this vaccine fully protected mice from lethal challenge and enhanced their recovery process. Our results indicate ...
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of ... The latter vaccines may also be whole viruses whose nucleic acids have been modified. ... Recombinant Vaccines; Vaccines, Synthetic; Synthetic Antigens; Synthetic Immunogens; Vaccines, Chemical; Vaccines, Molecular; ... Synthetic Vaccines (Recombinant Vaccines). Subscribe to New Research on Synthetic Vaccines Small synthetic peptides that mimic ...
Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to Develop Next-Generation Vaccines and Therapeutics. ... Under the collaboration, Synthetic Genomics will have exclusive access to LUNAR technology for vaccines and therapeutics, using ... About Synthetic Genomics, Inc.. Synthetic Genomics is programming the operating system of life to create sustainable solutions ... Continuing its legacy of scientific firsts in genomics and synthetic biology, Synthetic Genomics is harnessing the power of ...
Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. J P Tam ... Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system ... Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system ... Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system ...
... highlight the bright prospects for DNA vaccines to address many human diseases. ... highlight the bright prospects for DNA vaccines to address many human diseases. ... DNA vaccines have undergone a number of technological advancements that have incited renewed interest and heightened promise in ... DNA vaccines have undergone a number of technological advancements that have incited renewed interest and heightened promise in ...
Article on synthetic Hib vaccine CRISP Thesaurus entry on Synthetic Vaccines Web Health Centre: History of Vaccines v t e. ... A synthetic vaccine is a vaccine consisting mainly of synthetic peptides, carbohydrates, or antigens. They are usually ... Novartis Vaccine and Diagnostics, among other companies, developed a synthetic approach that very rapidly generates vaccine ... Patarroyo, Manuel E. (May 30, 2007). "Synthetic vaccine update: Applying lessons learned from recent SPf66 malarial vaccine ...
... into oligosaccharide and glycoconjugate construction for the creation and evaluation of glycopeptide-based vaccines. The basis ... Warren J.D., Geng X., Danishefsky S.J. (2006) Synthetic Glycopeptide-Based Vaccines. In: Wittmann V. (eds) Glycopeptides and ... Fattom A, Cho YH, Chu C, Fuller S, Fries L, Naso R (1999) Vaccine 17:126 CrossRefGoogle Scholar ... Ragupathi G, Cappello S, Yi SS, Canter D, Spassova M, Bornmann WG, Danishefsky SJ, Livingston PO (2002) Vaccine 20:1030 ...
Intervention Details: Drug: P53-SLP vaccine The P53-SLP vaccine is a vaccine consisting of a total of 10 long (30 amino acids ... p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer (ISA-P53-CTX). This study has been completed. ... p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer a Phase II Trial. ... Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer ...
QS-21 Augments the Antibody Response to a Synthetic Peptide Vaccine Compared to Alum. ... Evaluation of a synthetic HIV-1 p17-based candidate AIDS vaccine, HGP-30, Abstract M.C.P.13, V International Conference on ... QS-21 Augments the Antibody Response to a Synthetic Peptide Vaccine Compared to Alum. In: Goldstein A.L., Garaci E. (eds) ... Achour, A., Picard, O., Zagury, D., Sarin, P.S., Gallo, R.C., Naylor, P.H., and Goldstein, A.L., HGP-30, a synthetic analogue ...
Leveraging synthetic biology. The project will use recent scientific advances in synthetic biology to eliminate ASF viral ... There is currently no treatment or vaccine against African swine fever. A major roadblock to the development of a new vaccine ... Tackling this disease through the development of a vaccine will have the added effect of improving the lives of women in sub- ... With an estimated 34 million pigs in sub-Saharan Africa, the development of an African swine fever vaccine could benefit up to ...
Overview of Synthetic Peptide Vaccine Sales Industry. • Market Size (Value and Volume) analysis of Synthetic Peptide Vaccine ... Synthetic Peptide Vaccine Sales Industry Competition by Manufacturers, Type and Application. • Synthetic Peptide Vaccine Sales ... Synthetic Peptide Vaccine Sales Industry Technology and Development Trend. • Research Findings and Conclusion of Synthetic ... Synthetic Peptide Vaccine Sales Industry Report is a tool to assist novice as well as seeded players in gaining astute business ...
Some vaccine companies plan to create synthetic DNA which infects the hosts DNA with a synthetic genetic code. Downloading new ... synthetic vaccines remain speculative; well need to live with COVID-19 during the interim. To develop a coronavirus vaccine, ... The first coronavirus vaccines will enter Phase 2 testing soon but wont be ready for another 18 months. Synthetic biology may ... How is synthetic biology revolutionising vaccines? Self-replicating mRNA (SAM) is a technology that can help to make effective ...
... synthetic cells, wide range of applications of synthetic biology, declining cost of DNA sequencing & synthesizing, increasing R ... The growth of this market is primarily attributed to factors such as the increasing demand for synthetic genes & ... Synthetic Biology Market : Increasing Research in Synthetic Drugs and Vaccines. synthetic biology market is projected to reach ... The large share of the segment can be attributed to the rising demand for synthetic DNA, synthetic RNA, and synthetic genes, ...
Selectas proprietary Synthetic Vaccine Particle (SVP) platform creates a novel paradigm in immunotherapeutics and vaccines, ... Selecta, JDRF and Sanofi Extend Collaboration to Develop a Synthetic Vaccine Particle Immunotherapy for Type 1 Diabetes Joint ... program to develop a Synthetic Vaccine Particle (SVP™) immunotherapy with the long-term goal to treat and potentially prevent ...
Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer ... Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.. ... Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma ... On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 ...
Oral vaccine delivery: can it protect against non-mucosal pathogens? Expert Rev Vaccines. 2008;7:729-38.CrossRefPubMedCentral ... Pavot V, Rochereau N, Genin C, Verrier B, Paul S. New insights in mucosal vaccine development. Vaccine. 2012;30:142-54.CrossRef ... Evaluation of cell-surface displayed synthetic consensus dengue EDIII cells as a potent oral vaccine candidate. ... Oral vaccines have proven to be the best alternative as they avoid the risks commonly associated with conventional vaccines, ...
The research could lead to synthetic vaccines that protect people from the flu, HIV and other diseases. ... Yeates said that his labs method also could lead to the production of synthetic vaccines that would mimic what a cell sees ... New nanoscale protein container could lead to synthetic vaccines and medicine delivery method. by Stuart Wolpert, University of ... New nanoscale protein container could lead to synthetic vaccines and medicine delivery method. ...
  • The classical experimental approach for the development of an epitope-based vaccine involves the use of recombinant domains or overlapping 15-mer peptides spanning the full length of the target antigen, and the analysis of the induced antibody and/or T cell immune responses in vitro or in vivo. (
  • Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. (
  • A synthetic vaccine is a vaccine consisting mainly of synthetic peptides, carbohydrates, or antigens. (
  • The P53-SLP vaccine is a vaccine consisting of a total of 10 long (30 amino acids on average length) peptides, covering the p53 protein sequence from amino acid 70 to 251, combined with Montanide ISA51 an adjuvant with a sustained dendritic cell activating ability. (
  • In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. (
  • The antigens are selected based on the host HLA genotype, making them designer vaccine peptides. (
  • In addition to vaccine development, synthetic HLA peptides can be used for diagnostic purposes. (
  • SL-701 is a subcutaneously-administered cancer vaccine comprised of multiple synthetic peptides corresponding to targets on tumor bulk and cancer stem cells (CSCs). (
  • In another aspect this invention relates to immunogenic synthetic peptides having an invasin domain, a helper T cell epitope and a peptide hapten and methods of using these peptides to treat disease or provide protective immunity. (
  • Long synthetic peptides (LSPs) have a variety of important clinical uses as synthetic vaccines and drugs. (
  • G. Corradin, A. V. Kajava, A. Verdini, Long Synthetic Peptides for the Production of Vaccines and Drugs: A Technological Platform Coming of Age. (
  • Improved methods for producing long synthetic peptides, together with bioinformatics approaches, offer promise for the development of clinically relevant products. (
  • SL-701 is comprised of synthetic peptides corresponding to epitopes of targets overexpressed on glioblastoma multiforme (GBM) and other high-grade and low-grade gliomas and administered via direct subcutaneous injection. (
  • An enzyme immunoassay based on three synthetic peptides from the core, NS4, and NS5 regions of hepatitis C virus allowed the detection of antibodies in 100% of immunocompetent infected patients and in 91% of immunocompromised patients (hemodialysis and hemophiliac patients). (
  • Synthetic peptides have proven to be valuable tools for immunodiagnosis of hepatitis C virus (HCV) infection ( 8 , 10 , 18 ). (
  • Most of the available serological tests for HCV are based on the combined use of synthetic peptides and recombinant proteins. (
  • The aim of this study was to design an immunodiagnostic system for HCV based exclusively on synthetic peptides and suitable for epidemiological studies. (
  • Synthetic peptides corresponding to sequences within the structural proteins have been made and corresponding antisera prepared against them in rabbits. (
  • The Rice lab of Jeffrey Hartgerink has been studying synthetic collagen for a decade, teasing out the details of how it starts as three distinct peptides that twist into characteristic triple helices. (
  • The researchers made two classes of synthetic collagen peptides with the same chemical components but different arrangements and showed those with extensive sticky ends quickly self-assembled into fibers. (
  • We have tested overlapping synthetic peptides (OSP) representing a tumor antigen as a novel approach that bypasses the need for epitope mapping, since OSP contain all possible epitopes for both CD8 + and CD4 + T cells. (
  • Over the next five years, the SUPRAVACC (Supramolecular engineering of glycan-decorated peptides as synthetic vaccines) project will receive EUR 2 million in funding from the European Research Council. (
  • SPf66 is the first active vaccine against any organism to be based on synthetic peptides - fragments of proteins. (
  • These synthetic peptides mimic peptides from the malaria parasite Plasmodium falciparum. (
  • Synthetic long peptides (SLPs) derived from HPV16 E6 and E7 oncoproteins have been used for therapeutic vaccination in clinical trials with promising results. (
  • In a paper entitled, "Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses," Inovio scientists and collaborators demonstrated that the optimization of EP parameters including the decreased use of the current could generate stronger antibody and T cell responses to HIV and flu vaccine antigens in both guinea pigs and monkeys. (
  • However, recent improvements in our understanding of the immune responses required to combat each stage of infection will allow for intelligent design of both antigens and their associated delivery vaccine vehicles/vectors. (
  • Developing this chlamydia vaccine, along with the unique method that we have for making these antigens "on-demand" or as needed for use in vaccines, could be a godsend for the epidemic that's affecting the koalas, and also obviously has implications for treatment of diseases that affect humans as well-it's not just chlamydia, there's a whole host of disease antigens that are notoriously difficult to produce," He added. (
  • On the other hand, synthetic vaccines based on immunogenic epitopes offer advantages over traditional vaccines since they are chemically defined antigens free from deleterious effects. (
  • Thus, the MAP provided a general, but chemically unambiguous, approach for the preparation of carrier-bound antigens of predetermined and reproducible structure and might be suitable for generating vaccines. (
  • The fundamental idea behind DNA vaccines (also known as genetic vaccines) is to induce immune responses against recombinant antigens encoded by genetically engineered DNA plasmids expressed in vivo . (
  • With this knowledge and experience, we have begun to evaluate, in many cases at the clinical level, whether the human immune system is capable of mounting a response against such fully synthetic carbohydrate antigens in a focused and useful way. (
  • Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies. (
  • Among these partially protecting schistosome antigens are the following: glutathione S -transferase (GST) (Sm28 GST) ( 7 , 8 , 21 ), the muscle protein paramyosin (Sm97) ( 22 ), the irradiation-associated vaccine antigen (IrV-5) ( 27 , 28 ), triose-phosphate isomerase ( 9 , 23 ), the membrane antigen Sm23 ( 24 ), and fatty acid binding protein 14 (Sm14) ( 35 ). (
  • These candidate vaccine antigens are either ubiquitous enzymes usually involved in metabolic pathways, muscle proteins, or surface antigens, and they induced 30 to 60% protection against challenge infection. (
  • This vaccine format elicits B and T cell-dependent protection and targets multiple antigens, including the highly conserved viral nucleoprotein, indicating its usefulness as a cross-protective vaccine. (
  • In immunized mice, the aluminum oxyhydroxide-adsorbed formulation of 3M-052 enhanced antibody and TH1-type cellular immune responses to vaccine antigens for tuberculosis and HIV. (
  • In this Phase I project, we will use an innovative approach to produce synthetic nanoparticle vaccines carrying the RSV-G peptide coupled with RSV T-cell target antigens that favor IFN responses. (
  • Cancer vaccines that induce potent protective and therapeutic T-cell immunity against defined antigens are under active investigation. (
  • If tests in lab animals of the first such nanoparticle vaccine are any indication, it should be more potent than either old-fashioned viral vaccines like those for influenza or the viral antigens on their own (without the nanoparticle)," Begley writes. (
  • Yes, the use of biotechnology, GMOs or gene editing to develop antigens for treatments including vaccines are part of the solution. (
  • The use of synthetic antigens for diagnosis of infectious diseases : report of a WHO scientific group [meeting held in Geneva from 30 November to 4 December 1987]. (
  • LPV has been used to preserve stability and potency of several classes of vaccine antigens and biologics, including protein-based, monoclonal antibodies, whole-inactivated, and live-attenuated vaccines and viral vectors, according to VBI. (
  • Development of cancer vaccines from fully synthetic mucin-based glycopeptide antigens. (
  • Recent advances in adjuvant development, immunogen platforms for DNA vaccines and viral vectors also contributed to optimize immunogenicity. (
  • This review will focus on specific combined DNA vaccine approaches to improving immunogenicity in humans. (
  • The purpose of this study is to determine whether the addition of cyclophosphamide to the treatment with the p53-SLP vaccine improves clinical efficacy and immunogenicity of the p53-SLP vaccine in ovarian cancer patients. (
  • Although the mechanism of action of MPLA has not been fully eludicated, it has been suggested that MPLA improves vaccine immunogenicity by enhancing antigen presenting cell maturation [6]. (
  • Here, combinations of three synthetic polypeptides corresponding to amino (N), central repeat (R), and carboxyl (C) regions of the CS protein formulated in Montanide ISA 720 or Montanide ISA 51 adjuvants were assessed for immunogenicity in rodents and primates. (
  • They further suggest that the currently recommended prime-boost vaccination strategy of using a dose of PCV13, followed by a dose of PPV23, could enhance the vaccines' immunogenicity in immunosuppressed patients. (
  • The authors believe that theirs is the first report on the immunogenicity and tolerability of two currently licensed pneumococcal vaccines (polysaccharide and conjugate) in adults with SSc vs. controls. (
  • Importantly, results showed strong immune responses one year after the last dose, supporting the long-term immunogenicity of the vaccine - a particularly challenging area for Ebola vaccines. (
  • The successes with various CS vaccine strategies have been somewhat moderated by difficulties in production scale-up, poor immunogenicity, and dose-limiting toxicity of adjuvants. (
  • Efforts to develop recombinant subunit vaccines have met with limited success due to poor immunogenicity and short-lived responses. (
  • We have shown that vaccines made by this strategy improve the immunogenicity of both T-cell and antibody target epitopes without triggering adverse inflammatory reactions. (
  • Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. (
  • Of note, when the anti-Ebola virus glycoprotein DNA vaccine was by 2 injections delivered intradermally followed by electroporation, a strong immunogenicity was generated and was also 100% protective against the lethal Ebola virus-Makona challenge. (
  • Further, although reports of long-term immunogenicity following DNA or other experimental vaccine administration are lacking, results showed that the anti-Ebola virus glycoprotein DNA vaccine induced long-term immune responses in the nonhuman primates. (
  • The resulting vaccine was thought to have struck a balance between reduced virulence and preserved immunogenicity ( 2 ). (
  • In a letter to the NBSB from Dr. Nicole Lurie, HHS Assistant Secretary for Preparedness and Response (ASPR), said currently there are no safety, immunogenicity, or efficacy data in pediatric populations that would allow the US Food and Drug Administration (FDA) to evaluate the anthrax vaccine for pediatric use under an EUA. (
  • The self-amplifying RNA-based therapeutic triggers rapid and immediate antigen expression within host cells, stronger T-cell response (including when the host is already infected), and lower dose requirements compared to traditional RNA-based vaccine and therapeutic approaches. (
  • 2010. TLR4 Ligands Augment Antigen-Specific CD8+ T Lymphocyte Responses Elicited by a Viral Vaccine Vector. (
  • To overcome the antigenic diversity of H3N2 viruses, Weiner and colleagues used H3N2 strains from 1968 to the present retrieved from the Influenza Research Database to generate four synthetic common sequences of the hemagglutinin antigen (HA), a protein present on the viral surface. (
  • The self-amplifying RNA-based vaccine triggers rapid and immediate antigen expression within host cells, which induces strong T cell and B cell responses. (
  • Incorporation of TDB combined with the synthetic amphiphilic cationic lipid compound dimethyldioctadecylammonium (DDA) into liposomes, known as CAF01, has been shown to strongly enhance cellular and humoral responses against a protein antigen [2]. (
  • Protective efficacy of a lipid antigen vaccine in a guinea pig model of tuberculosis. (
  • Selecta Biosciences Inc., a clinical stage biotechnology company that is developing an innovative class of targeted antigen-specific immune therapies with synthetic vaccine particles (SVPs), recently announced that SVP may be crucial to developing an innovative vaccine technology targeting mucosal tissues. (
  • With this grant, Selecta's past and committed grant funding now exceeds $20 million, strategically enabling us to work on therapeutic and prophylactic vaccines in parallel to our core focus on antigen-specific immune tolerance. (
  • LPV is designed to enclose and protect the antigen of a vaccine or biologic using a proprietary formulation and process. (
  • A recent study published in the MDPI journal, Pathogens, describes a coronavirus peptide vaccine antigen in the form of nanodiamond-based formulations, that demonstrated a robust and long-lasting immune response. (
  • To demonstrate its utility, we conjugated the tumor-specific monosaccharide antigen Tn to this novel carrier protein and successfully developed a Tn vaccine against cancer in animal models. (
  • Therefore, the efficacy yield of a synthetic vaccine can be potentiated by using the proper combination of target epitopes. (
  • However, despite promising studies in small animal models and improved efficacy in large animal models, the clinical ability of DNA vaccines still remains unproven. (
  • Selecta's proprietary Synthetic Vaccine Particle ( SVP ) platform creates a novel paradigm in immunotherapeutics and vaccines, enabling completely new applications while offering the potential of improved efficacy and safety profiles. (
  • The synthetic peptide vaccine developed by the University of Pittsburgh has previously demonstrated single-agent clinical efficacy, including complete responses (CRs), in Phase 1/2 trials in both adults and children with high-grade glioma (HGG), including glioblastoma multiforme (GBM). (
  • Commercial vaccine efficacy against H3N2 in 2017/2018 was low and contributed to a greater rate of pneumonia and influenza-associated deaths. (
  • A synthetic peptide vaccine (J8-DT) from the conserved region of the M protein has shown efficacy against disease that follows i.p. inoculation of bacteria. (
  • For nearly a century, aluminum salts have been the most widely used vaccine adjuvant formulation, and have thus established a history of safety and efficacy. (
  • They demonstrated efficacy of the novel vaccine candidates and durability of the immune responses in animal models. (
  • This project will generate a set of synthetic vaccine candidates and test their safety and efficacy in swine, which is expected to significantly advance the development of an urgently needed African swine fever vaccine. (
  • Inadequate stimulation of the neonatal immune system and the requirement for multiple booster administrations have limited the efficacy of the majority of current vaccine formulations. (
  • Furthermore, the current global shortage in BCG calls attention to the current lack of scalable synthetic formulations that can achieve similar and potentially improved efficacy relative to immunization with live attenuated pathogens. (
  • The deliverable of this project is one or more LbL RSV-G vaccine candidates with demonstrated safety and efficacy in animal models;these candidates will be further developed in a subsequent Phase II project that will complete the steps necessary for Investigational New Drug application filing and eventual clinical testing. (
  • For optimization of the efficacy of naked RNA vaccines, a better understanding of in vivo pharmacology of directly administered RNA in animals and humans is required. (
  • The current study, as a continuation of this work, explored the immunopharmacologic properties of such optimized RNA upon direct administration, as well as its mode of action and efficacy as part of a preclinical vaccine development program. (
  • Our proof-of-concept data demonstrate the safety and efficacy of peptide library-based cancer vaccines that obviates the need to identify epitopes or MHC backgrounds of the vaccinees. (
  • Vaccination with pH3HA induced robust antibodies against the 1968 pandemic H3N2 as well as contemporary H3N2 strains that were components of commercially available vaccines from 2015/2016 and 2017/2018. (
  • Sarah Elliott et al, A Synthetic Micro-Consensus DNA Vaccine Generates Comprehensive Influenza-A H3N2 Immunity and Protects Mice Against Lethal Challenge by Multiple H3N2 Viruses, Human Gene Therapy (2018). (
  • 2018 Vaccine 36(34):5210-5217. (
  • PHILADELPHIA - (October 10, 2018) - A novel synthetic DNA vaccine developed based on technology pioneered by scientists at The Wistar Institute Vaccine & Immunotherapy Center offers complete protection from Zaire Ebolavirus (EBOV) infection in promising preclinical research. (
  • When new flu strain emerges, government agencies normally send samples to vaccine manufacturers, who grow large numbers of the pathogen in chicken eggs as starting material for vaccines, says Philip Dormitzer , leader of viral vaccine research for Novartis. (
  • The idea is to build a synthetic virus based on sequence data that can be distributed much more quickly than actual viral material harvested at the site of an outbreak. (
  • The synthetic viral genome combines a genomic backbone common to many flu viruses with genes specific to the strains seen in a new outbreak. (
  • In addition, different computational tools allow the determination of crucial gene(s) through comparative analyses between different pathogenic strains Alternatively, carbohydrates have been considered as key targets in developing safe and effective vaccines to combat cancer, bacterial and viral infections. (
  • The project will use recent scientific advances in synthetic biology to eliminate ASF viral proteins that are responsible for causing disease. (
  • essential for virus survival and stimulation of swine protective immune responses will be identified with the aid of bioinformatics and re-assembled into a recombinant ASF live viral vaccine. (
  • Thus, the oral administration of genetically engineered yeast whole cells displaying biologically active Co1-scEDIII fusion protein without any further processing shows prospective as a potent oral vaccine candidate against dengue viral infection. (
  • There is also a need for improvements in rapid selection and deployment against newly emergent viral strains and synthetic DNA vaccines represent an important tool to reach this goal. (
  • Thus a vaccine targeting these viral proteins is an "ideal candidate" to create strong immune responses, with the additional benefit of not generating autoimmune-related pathologies. (
  • These data indicate that covalent linkage of well-ordered trimers to liposomes in high-density array displays multiple advantages and Enveloped viruses typically encode a surface-bound glycoprotein that mediates viral entry into host cells and is a primary target for vaccine design. (
  • They confirmed the structure and showed that the external features of the new synthetic vaccine were identical to those of the poliovirus, albeit it had not viral materials within to trigger actual infection. (
  • Synthetic non-viral based DNA technology allows for rapid vaccine development by delivery directly into the skin, resulting in consistent, potent and rapid immunity compared to traditional vaccine approaches," said lead researcher David B. Weiner, Ph.D. , executive vice president and director of Wistar's Vaccine & Immunotherapy Center, and W.W. Smith Charitable Trust Professor in Cancer Research. (
  • Unlike traditional vaccines -- which build a recipient's immunity against a virus by introducing a small amount of viral material and letting the immune system build up antibody defenses -- this new Zika vaccine candidate, GLS-5700, utilizes a novel inoculation method: packaging synthesized portions of the virus. (
  • The immune responses elicited by LbL nanocapsules conspicuously do not include antibody responses to the matrix polypeptides used to produce the biofilm, thereby avoiding the so-called vector or carrier effect that has hampered development of many viral vectored vaccines. (
  • The mRNA vaccines are not new: vaccines that are based on attenuated mRNA viruses, such as Mumps, Measles, and Rubella, immunize by delivering their mRNAs into the cells of the vaccinated individual, who produces the viral proteins that then prime the immune response. (
  • His major career activities have included preclinical and clinical research on viral (e.g., hepatitis, HIV, smallpox), rickettsial and bacterial (TB) vaccines, immune globulins and diagnostics for detection, treatment and prevention of infectious diseases. (
  • Most human vaccines are based on inactivated viruses or viral proteins. (
  • There is a wide range of applications for synthetic viral technology such as medical treatments, investigative tools, and reviving organisms. (
  • There are no vaccines or therapies available to treat or prevent this emerging infection. (
  • Vaccines interact with patient immune systems to produce active immunity, which provides protection from disease. (
  • The effectiveness of this vaccine was evaluated in preclinical studies that showed a single immunization elicited broad T and B cell immune responses in mice similar to those induced naturally in POWV-infected individuals, and that vaccine-induced immunity provided protection in a POWV challenge animal model. (
  • Thus, the development of an efficacious dengue vaccine conferring simultaneous and durable immunity to each of the four DENV serotypes has not yet been developed despite years of research. (
  • Currently available vaccines for the prevention of seasonal influenza virus infection have limited ability to induce immunity against diverse H3N2 viruses, an influenza A subtype that has led to high morbidity and mortality in recent years. (
  • Dave Rowlands, Emeritus Professor of Virology at the University of Leeds and Principal Investigator on this project, said: "Small-scale laboratory tests demonstrated that the groundbreaking synthetic vaccine provided animals with immunity from the disease similar to the existing widely used vaccine. (
  • Here we show that mRNA vaccines induce balanced, long-lived and protective immunity to influenza A virus infections in even very young and very old mice and that the vaccine remains protective upon thermal stress. (
  • A novel synthetic DNA vaccine can, for the first time, induce protective immunity against the Middle East Respiratory Syndrome (MERS) coronavirus in animal species, reported researchers from the Perelman School of Medicine at the University of Pennsylvania . (
  • Thus there is a critical need to improve the majority of current vaccine formulations to achieve one-shot neonatal immunization while ensuring programming of neonatal immunity for retention of heterologous effects of attenuated vaccines. (
  • A synthetic DNA vaccine may be a reasonable candidate because it is non-live, nonviral, and able to drive humoral and T-cell immunity along with establishing a long-term immunologic memory. (
  • Research firm Seattle BioMed received an $8.9 million grant from the Bill & Melinda Gates Foundation to identify biomarkers of protective immunity for malaria vaccines. (
  • But malaria is a special case because even natural immunity is only temporary and partial, and years of research have failed to produce a vaccine. (
  • Whilst getting the pathogen parts to stick to the carrier VLP, often problems such as misassembly or misfolding arise that make the vaccine ineffective at generating protective immunity. (
  • In: Vaccines: new generation immunological adjvant / Gregoriadis, G., - p. 127 - 133. (
  • According to a research abstract published on the SNO meeting website, University of Pittsburgh investigators will report on the safety and immunological responses achieved with the Pitt vaccine in an additional indication, adults with newly diagnosed or recurrent low-grade glioma (LGG) (n=23). (
  • 2008. Cationic liposomes formulated with synthetic mycobacterial cord factor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. (
  • The research team concluded that the direct injection synthetic peptide vaccine, now being developed by Stemline as SL-701, demonstrated both immunological and clinical activity in children with malignant glioma. (
  • These results suggest that immunomodulating drugs, but not SSc itself and/or immunological disturbance as a part of this disease, affect the ability to produce a sufficient amount of vaccine-specific antibodies, but not their function," the researchers write. (
  • In ferrets and pigs, mRNA vaccines induce immunological correlates of protection and protective effects similar to those of a licensed influenza vaccine in pigs. (
  • These off-target nonspecific benefits are often referred to as "heterologous" effects and suggest that immunostimulation by BCG and other attenuated vaccines may program neonatal immune cells for lasting immunological advantages. (
  • We have identified the principle immunological responses elicited by the BCG vaccine and used these findings to rationally design a synthetic nanocarrier formulation to mimic and improve upon BCG-induced immunostimulation. (
  • The most important role of vaccines is the induction of immunological memory, which is crucial for long-term protection against pathogens. (
  • The immunological properties of the fully synthetic vaccines will be evaluated by Professor Pol Besenius and his team in cooperation with Professor Edgar Schmitt's group at the Institute of Immunology of the Mainz University Medical Center. (
  • The researchers will be assessing this supramolecular engineering approach with respect to its ability to induce immunological protection against bacterial diseases and also its potential use as anti-tumor vaccines. (
  • Phase I data of UB-311, a synthetic peptide vaccine targeting amyloid beta, showed that the drug was able to generate antibodies to specific amyloid beta oligomers and fibrils with no decrease in antibody levels in patients of advanced age. (
  • 3 The study's hypothesis was that these two adjuvants function by different means to increase antibody titer to a synthetic peptide immunogen. (
  • Kirkley J.E., Naylor P.H., Marciani D.J., Kensil C.R., Newman M., Goldstein A.L. (1992) QS-21 Augments the Antibody Response to a Synthetic Peptide Vaccine Compared to Alum. (
  • Dengue vaccine development is complicated by the possibility of vaccine-enhanced severe dengue disease due to antibody-dependent enhancement by pre-existing cross-reactivity, as well as homotypic antibodies. (
  • All mice immunized with the synthetic DNA vaccine developed broad, robust antibody responses against HA and effective cellular immune responses including CD4 and CD8 T cell responses. (
  • 2005. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. (
  • NEW YORK (Reuters Health)- Pneumococcal vaccination yields a satisfactory antibody response in patients with systemic sclerosis (SSc), but synthetic disease-modifying antirheumatic drugs (DMARDs) might reduce the vaccine response in these individuals, according to a report from Sweden. (
  • For both vaccines, the antibody response to two capsular polysaccharide serotypes (6B and 23F), as well as functionality of antibodies for 23F, was as good in the SSc patients not receiving DMARDs as in the controls. (
  • Pneumococcal vaccination is safe and immunogenic in patients with SSc, although treatment with DMARDs may decrease the vaccine-specific antibody response," they conclude. (
  • The detected antibody levels were equal or higher to those reported for other vaccines currently being evaluated in the clinic, according to the study. (
  • In rodent experiments, synthetic pancoronaviral peptide-conjugated NDs were able to readily induce antibody responses following injection. (
  • Details of this work appeared October 4 in the journal Cancer Research , in an article titled, " Synthetic DNA-encoded monoclonal antibody delivery of anti-CTLA-4 antibodies induces tumor shrinkage in vivo . (
  • This showed that linking can be done simply and quickly to produce stable vaccines that generated robust antibody responses. (
  • C ) The designed vaccines will be based on a standardized 'chassis' that can hold several different types of pathogenic epitopes (the surface molecules necessary for the protective immune responses), so development of the next vaccine(s) will be much easier and faster. (
  • These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. (
  • 2020) A novel synthetic DNA vaccine elicits protective immune responses against Powassan virus. (
  • Traditional vaccines contain PAMPs and induce strong immune responses, while recombinant vaccines are less potent. (
  • These promising results, coupled with recent clinical trials that have shown enhanced immune responses in humans, highlight the bright prospects for DNA vaccines to address many human diseases. (
  • Unlike other viruses, the ASF virus induces more complex immune responses that require intricate virus manipulation prior to the design and development of a vaccine. (
  • The recombinant vaccine will have the capacity to regenerate and stimulate immune responses without causing disease. (
  • The Pitt Vaccine was determined to be well-tolerated and induced specific and sustained immune responses against its brain tumor targets. (
  • Now, Wistar scientists have engineered a synthetic DNA vaccine shown to produce broad immune responses against these H3N2 viruses. (
  • The pH3HA vaccine represents a unique micro-consensus approach to producing immune responses to antigenically related-yet diverse, seasonal influenza A H3N2 viruses," Weiner said. (
  • The team concluded that the Pitt vaccine, now being developed by Stemline as SL-701, was well tolerated and demonstrated immune responses in high risk adult patients with LGG. (
  • The disease induces complex immune responses that require intricate virus manipulation prior to designing and developing a vaccine. (
  • Current results in multiple model systems show that LbL nanocapsule vaccines elicit potent immune responses following one or two immunizations without adjuvants, avoiding undesirable responses such as the release of inflammatory cytokines. (
  • This project will yield synthetic nanocapsule vaccine candidates that elicit potent CS-specific immune responses and provide protection from malaria without the use of toxic adjuvants. (
  • Despite numerous shortcomings, including waning protection following childhood and ineffectiveness for adults, the Bacille Calmette-Guerin (BCG) attenuated vaccine against Mycobacterium tuberculosis (Mtb) safely elicits Th1 neonatal immune responses and requires only a single administration at the time of birth. (
  • Furthermore, patients immunized with BCG and other attenuated vaccines have demonstrated enhanced and more effective immune responses upon infection with unrelated pathogens later in life resulting lowered overall mortality. (
  • These findings suggest that the complex immune responses generated by attenuated vaccines can be accurately mimicked synthetically, allowing extensive customization, optimization and rapid scalable production of subunit vaccine formulations that would otherwise not be possible. (
  • Since the vaccines contain a portion of the virus responsible for both infection and host inflammation, vaccine-induced immune responses will not only reduce the rate of RSV infectivity but will also alleviate the lung inflammation associated with RSV disease. (
  • Although there have been significant breakthroughs in the Ebola virus disease vaccine development field, there remains an important need for prophylactic anti-Ebola virus vaccine candidates that elicit long-lasting immune responses. (
  • These streptococcal SVLP-based vaccine candidates are shown to elicit strong humoral immune responses in mice. (
  • In light of the recent availability of genomic tools, we believe that in the near future an increasing number of vaccine candidates, composed of defined epitopes, will be available for synthetic vaccines showing improved protection. (
  • Our results indicate that a single construct expressing multiple epitopes, which stimulate different arms of the immune system, might be an appropriate candidate when the synthetic recombinant vaccine approach is considered. (
  • The goal of this project is to produce novel synthetic malaria vaccines based on epitopes of the circumsporozoite (CS) protein of Plasmodium falciparum, the causative agent of human malaria. (
  • While there is no approved vaccine, previous work has shown that the CS protein of the sporozoite stage contains a number of candidate vaccine epitopes that are recognized by antibodies and T-cells of protected hosts. (
  • To overcome these issues, an innovative approach will be employed which uses layer-by-layer (LbL) fabrication of artificial biofilms to incorporate the CS epitopes in synthetic nanocapsule vaccines. (
  • The use of a vaccine peptide usually entails the conjugation of the antigenic epitope to a more immunogenic carrier protein, or mounting the epitopes on a multivalent nanostructure. (
  • In contrast, based on the same Replikins epitopes, Replikins Synthetic TransFlu™ Vaccine was first prepared in 2008, exists now, was successful in its first trial (12), and is undergoing further testing. (
  • Here, we set out to demonstrate that this approach can yield vaccine candidates able to elicit a protective immune response, using epitopes derived from the proline-rich region of pneumococcal surface protein A (PspA). (
  • In the European H2020 funded project MycoSynVac (2015-2020), CRG together with INRA, the global healthcare leader MSD Animal Health , and other partners across Europe, are now working on the first synthetic biology-derived animal vaccine. (
  • E ) Last but not least, once approved for farm animals, the next goal will be synthetic biology vaccines for human infections with an even bigger market and impact. (
  • Synthetic biology could be a source of new medical treatments. (
  • Synthetic biology is breathing new life into the old-fashioned world of vaccine production, raising hopes that manufacturers could release vaccines much more quickly when outbreaks occur. (
  • At a meeting on synthetic biology held at MIT, the drug company Novartis said it has synthesized hybrid flu genomes in a process that could shave weeks off the time required to produce vaccines. (
  • Mammalian synthetic biology, which involves modifying mammalian genetic circuits, is still in "relative infancy," says Jim Collins , a synthetic biologist at Boston University. (
  • Some efforts to apply synthetic biology to health focus on programming stem cells to behave like naturally occurring cells that have been lost because of disease. (
  • A multidisciplinary scientific team at Lawrence Livermore National Laboratory (LLNL) has made significant advances in developing a vaccine for chlamydia using synthetic biology, sponsored by a two-year National Institutes of Health (NIH ) grant. (
  • Continuing its legacy of scientific firsts in genomics and synthetic biology, Synthetic Genomics is harnessing the power of nature to improve quality of life. (
  • The corvid 19 virus mutates like crazy making normal approaches obsolete making a new approach necessary with synthetic biology. (
  • What synthetic DNA could do is allow corporations to download anything they want into the biology of the host like programmable biology. (
  • Synthetic biology may offer a "universal coronavirus vaccine" that can be quickly modified to combat future mutated forms at the speed of light. (
  • Once this hypothetical synthetic DNA was in you they could download information into it at a distance similar to wireless downloads into your phone however it would be directly be into your biology. (
  • I think this technology we are seeing is the tip of the iceberg with what's happening in the realm of synthetic biology. (
  • Can synthetic biology protect us from coronavirus? (
  • The National Institutes of Health hopes synthetic biology can engineer vaccines that outperform nature. (
  • Although the Gates Foundation is spreading its bets among several cutting-edge vaccine platforms, including those using genetic material, one based on synthetic biology has real promise. (
  • How is synthetic biology revolutionising vaccines? (
  • EMAILWIRE.COM , December 12, 2020 ) The growth of this market is primarily attributed to factors such as the increasing demand for synthetic genes & synthetic cells, wide range of applications of synthetic biology, declining cost of DNA sequencing & synthesizing, increasing R&D funding & initiatives in synthetic biology, and increasing investments in the market. (
  • Factors such as growth in the number of pharmaceutical & biopharmaceutical companies, the increasing number of healthcare & life science facilities, and increasing requirements for regulatory compliance in pharmaceutical and biopharmaceutical companies, growing number of international alliances, heavy funding for synthetic biology research, and strong government support are expected to drive the growth of these markets during the forecast period. (
  • North America dominated the global synthetic biology market, followed by Europe. (
  • When it was needed, synthetic biology began to deliver on its promise. (
  • Synthetic biology applies engineering principles to biological processes, and it is driven by the belief that creating standardised biological parts or building novel biological systems can be of greater benefit to us. (
  • by delivering on its promise, synthetic biology can provide a much-needed boost to innovation in the sector. (
  • This partnership with Ceva, a leader in animal health, highlights the promise in deploying our synthetic biology capabilities to build RNA systems capable of improving global health in a variety of ways. (
  • Dave Stuart, Director of Life Sciences at Diamond and Professor of Structural Biology at University of Oxford, explains: "We were inspired by the successful synthetic vaccine for foot-and-mouth disease, also investigated at Diamond as part of UK research collaboration. (
  • In the first phase of the project, researchers successfully used synthetic biology tools to modify and assemble a synthetic African swine fever virus genome. (
  • As reported by Sharon Begley in STAT , NIH is looking toward synthetic biology for the next advancement in vaccination development. (
  • He is currently heading the Biology/Biotech R&D and Algae to Oil R&D at Reliance Industries with a focus on biofuel, food, feed, nutrition and biomaterials produced through synthetic biology route. (
  • Lessons learned from COVID-19 vaccines could advance synthetic biology. (
  • Intellectual property waivers for COVID-19 vaccines could change the course of synthetic biology, enabling the democratic distribution of technologies. (
  • Unlike traditional vaccines, there is no chance that the empty shell vaccine could revert to an infectious form," said Dave Stuart, Life Sciences Director at Diamond, and MRC Professor of Structural Biology at the University of Oxford in an article on the BBC website . (
  • Breakthrough or not, the results raise questions - not only for the biology of malaria, but also for the heated politics of vaccine research. (
  • It is a multidisciplinary research field at the intersection of virology, synthetic biology, computational biology, and DNA nanotechnology, from which it borrows and integrates its concepts and methodologies. (
  • Respiratory Syncytial Virus (RSV) G Protein Vaccines With Central Conserved Domain Mutations Induce CX3C-CX3CR1 Blocking Antibodies. (
  • The vaccine also generated potentially protective antibodies in blood drawn from camels, the purported source of MERS transmission in the Middle East. (
  • In addition, the vaccine induced antibodies that are linked with protection in camels, a species that is thought to be a major source of transmission to humans in the Middle East, showing that this vaccine could be deployed to break this this link in the MERS transmission cycle. (
  • Remarkably, the 30 µg of mRNA that are contained in the first approved anti-COVID-19 vaccine are sufficient for generating high levels of neutralizing antibodies against the virus in all injected volunteers (including participants over 65 years old). (
  • This method of HIV treatment is based on placing genes that code for synthetic antibodies against HIV into CD4 cells. (
  • The new method is the first to create synthetic recognition sites (similar to natural antibodies) for proteins and to couple them directly to a powerful nanosensor such as a carbon nanotube. (
  • The researchers believe their synthetic molecular recognition agents are an improvement over existing natural systems based on antibodies or DNA sequences known as aptamers, which are more fragile and tend to degrade over time. (
  • They developed a synthetic, sequence-optimized DNA plasmid designed to encode anti-mouse CTLA-4 monoclonal antibodies. (
  • The Tn vaccine effectively elicited high-titer IgG1 antibodies against Tn in immunized mice, and effectively suppressed the development of prostate cancer in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mice. (
  • The work discussed in the group's journal article includes a patent-pending technique unique to Lawrence Livermore (developed in partnership with Synthetic Genomics, Inc.) that has produced high-yield, functional, immunogenic chlamydia MOMP-a breakthrough in MOMP production techniques. (
  • In spite of the immunogenic weakness previously attributed to epitope-based vaccines a synthetic vaccine containing a 17 amino acid-epitope of the Pseudomonas aeruginosa Type IV pilus exceeded the protective potential of its cognate protein composed of 115 amino acids. (
  • Both vaccine formulations were highly immunogenic in both species. (
  • The same pattern was seen irrespective of disease activity, type of disease (diffuse or limited) or whether patients were vaccinated with a polysaccharide or a more immunogenic conjugate vaccine," she adds. (
  • Intradermal-electroporation delivery is an alternate route for vaccine administration that is immunogenic and potentially dose sparing, which are potential advantages for vaccine delivery in an outbreak setting and for more sensitive populations. (
  • Conversely, protein-based vaccines are less immunogenic, and as a result, a greater number of doses may be required. (
  • In fact Mycoplasma is not just a beautiful model organism for synthetic genomics. (
  • SAN DIEGO, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Arcturus Therapeutics, Inc., a leading RNA medicines company, and Synthetic Genomics, Inc. announced today that they have entered into a research collaboration and worldwide license agreement to develop self-amplifying RNA-based vaccines and therapeutics in both human and animal health. (
  • The collaboration will bring together Arcturus's LUNAR™ lipid-mediated delivery platform with Synthetic Genomics' RNA replicon platform to potentially enable more efficacious and lower cost vaccines and therapeutics. (
  • Under the collaboration, Synthetic Genomics will have exclusive access to LUNAR technology for vaccines and therapeutics, using self-amplifying RNA. (
  • This agreement with Synthetic Genomics is in line with our corporate strategy to form strategic collaborations that leverage our proprietary technologies," said Joseph Payne, president and chief executive officer of Arcturus. (
  • Synthetic Genomics' RNA replicons provide the genetic instructions to the body's own cells to produce ample amounts of protein and unleash a powerful immune response. (
  • Combining Synthetic Genomics' replicons with Arcturus' LUNAR technology may enable the replicon RNA to avoid degradation and target the tissues and cell types needed to promote a protective immune response or drive expression of therapeutic proteins. (
  • We have made tremendous progress in programming our replicon RNA system to develop next generation vaccines and therapeutics," said Oliver Fetzer, Ph.D., chief executive officer of Synthetic Genomics. (
  • About Synthetic Genomics, Inc. (
  • Synthetic Genomics is programming the operating system of life to create sustainable solutions for humankind's most pressing issues, from the wellbeing of our population to the health of our planet. (
  • With an unmatched understanding of how DNA drives the function of cells - the basic biological units of all living organisms - Synthetic Genomics modifies and writes genomes to enable transformative products in the areas of vaccines, medicines, nutrition, and biotechnology research. (
  • In addition to designing novel organisms that overcome fundamental hurdles of scientific research and medicine, Synthetic Genomics pursues partnerships with organizations seeking to dramatically improve upon existing products in health care, energy and other sectors. (
  • LA JOLLA, Calif., Oct. 7 /PRNewswire/ -- The company Synthetic Genomics Inc. (SGI) and the not-for-profit research organization, the J. Craig Venter Institute (JCVI) today announced the formation of a new company, Synthetic Genomics Vaccines Inc. (SGVI). (
  • SGVI is also announcing a three-year collaboration agreement with Novartis to apply synthetic genomics tools and technologies to accelerate the production of the influenza seed strains required for vaccine manufacturing. (
  • Novartis has been working with JCVI for more than a decade to apply their findings in the genomics field to develop novel vaccines that prevent disease. (
  • The last collaboration introduced the use of genomics in vaccines research, a technology today known as "reverse vaccinology. (
  • Using these same synthetic genomics advances it is conceivable that more universal vaccines could be developed to target a wide range of infectious disease agents in addition to new influenza vaccines. (
  • We are excited to apply our advanced synthetic genomics technologies to revolutionize vaccine production. (
  • SGVI, a privately held company founded in 2010 by Synthetic Genomics, Inc. and the J. Craig Venter Institute, is dedicated to the development of new vaccines using the advanced tools and technologies of synthetic genomics. (
  • SOURCE Synthetic Genomics Inc. (
  • San Diego, CA - October 31, 2017 - Synthetic Genomics, Inc . announced today that the company has entered into a collaboration with Ceva Santé Animale to utilize Synthetic Genomics' next-generation synthetic RNA replicon platform to develop vaccines for livestock. (
  • Synthetic Genomics' RNA replicons are programed to deliver genetic instructions to a body's own cells to unleash a powerful immune response against a specific disease. (
  • We have made tremendous progress to date in programming RNA to develop next-generation vaccines that are multigenic, tunable and, most importantly, scalable for commercially competitive markets, such as animal health," said Oliver Fetzer, Ph.D., chief executive officer of Synthetic Genomics. (
  • Exxon expects to invest more than $600 million dollars to work with Synthetic Genomics Inc. - the company co-founded by Venter - to develop algae that can turn sunlight and carbon dioxide into energy. (
  • We previously hypothesized that pressures to minimize adverse effects and maintain tuberculin reactivity during this time resulted in impotent vaccines that consistently induce tuberculin sensitivity with immunization ( 3 ). (
  • The privately held company will focus on developing next generation vaccines using JCVI's genomic sequencing and synthetic genomic research expertise, coupled with the intellectual property and business acumen of SGI, to significantly advance and enhance vaccine development. (
  • These methods advance the capacity to produce next generation vaccines and offer special promise as a tool for constructing the complicated synthetic viruses that will likely be needed to treat cancer," Evans said. (
  • Targeting this patient population provides a window-of-opportunity to design and manufacture the personalized cancer vaccines, maximizes the potential benefit from the vaccine as the regulatory networks associated with metastatic disease are not present, and balances risk in this patient population with extremely high risk for disease recurrence but no other treatment options. (
  • Importantly, administration of pLHMGA nanoparticles was not associated with adverse effects and therefore these biodegradable nanoparticles are excellent substitutes for IFA in cancer vaccines. (
  • In this report, the global Synthetic Peptide Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. (
  • 1.2.5 Other 1.3 Global Synthetic Peptide Vaccine Market by Application/End Users 1.3.1 Global Synthetic Peptide Vaccine Sales (Volume) and Market Share Comparison by Application (2012-2022) 1.3.2 Prostate Cancer? (
  • The Global Synthetic Peptide Vaccine market consists of different international, regional, and local vendors. (
  • What are the key factors driving the global Synthetic Peptide Vaccine market? (
  • Who are the key market players and what are their strategies in the global Synthetic Peptide Vaccine market? (
  • Clinical responses to the p53 synthetic long peptide vaccine preceded by cyclophosphamide will be assessed by measurement of serum CA-125 levels and CT-scan. (
  • On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. (
  • Over the last few years, several avenues of study have suggested that the adverse inflammatory responses associated with RSV infection, and perhaps the failure of the FI-RSV vaccine, are linked to the RSV-G protein which plays a critical role in virus attachment to target cells. (
  • Peptide-based vaccines, one of several anti-tumor immunization strategies currently under investigation, can elicit both MHC Class I-restricted (CD8 + ) and Class II-restricted (CD4 + ) responses. (
  • The first coronavirus vaccines will enter Phase 2 testing soon but won't be ready for another 18 months. (
  • The US Food and Drug Administration requested that production of the Johnson & Johnson coronavirus vaccine be halted at a factory that previously reportedly ruined about 15 million doses of the shot. (
  • The distribution of these vaccines throughout the world will bring a halt to the coronavirus pandemic. (
  • The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. (
  • As companies hurry to test potential vaccines, the National Institute of Health (NIH) is hoping new bio-engineering techniques to help us restrain coronavirus-and its next mutation, too. (
  • A synthetic pan-coronavirus peptide called heptad repeat 2 (HR2) peptide was employed. (
  • In this work, this protective peptide was expressed in the flagellin of a Salmonella vaccine strain, and the isolated recombinant flagella were used for immunization of mice. (
  • The researchers optimized a shorter, dose-sparing, immunization regimen and simplified vaccine administration directly into the skin. (
  • Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. (
  • Thus, there is a need to develop therapeutic vaccines for HPV-related tumours. (
  • The anti-COVID-19 mRNA vaccine (coding the SARS-CoV-2 spike protein) is the third synthetic RNA therapeutic being approved. (
  • The significant protection in mice demonstrated by our vaccine is highly encouraging and strongly supports the importance of this vaccine approach for further study. (
  • Furthermore, this vaccine fully protected mice from lethal challenge and enhanced their recovery process. (
  • The scientists administered the vaccine or placebo to mice and a booster vaccine two weeks later. (
  • When they tested their vaccine in mice with HPV16-induced tumours, they found that TriVax containing a small synthetic fragment (peptide) of the E7 protein "induced tumour clearance in 100 percent of the treated mice" while the unvaccinated mice with HPV-induced tumours had their tumours grow "at a fast rate. (
  • Mice receiving the combination vaccine were strongly protected against pyoderma and bacteremia, as evidenced by a 100-1000-fold reduction in bacterial burden following challenge. (
  • BALB/c mice and Aotus monkeys were divided into test and control groups and were immunized three times with doses of 50 and 100 μg of vaccine or placebo. (
  • Using synthetic messenger RNA (mRNA) instead of proteins purified from viruses, German scientists have shown they can protect mice, ferrets, and pigs against influenza. (
  • That saves time and may produce more effective vaccines. (
  • Next, the researchers will test whether the technique can combat malaria and HIV, both of which currently lack effective vaccines. (
  • However, effective vaccines against global health threats such as HIV, parasite infections and tumors are difficult to achieve. (
  • Self-replicating mRNA (SAM) is a technology that can help to make effective vaccines more quickly. (
  • Thus, further studies on the development of potent and effective vaccines are required. (
  • The technology opens the door to more effective vaccines and therapeutics. (
  • The vaccines would provoke a strong response from the body's immune system and perhaps provide better protection from diseases than traditional vaccines. (
  • Traditional vaccines and approaches have not been effective in treating many of the serious and chronic infectious diseases that survive in mucosa. (
  • For the case of Chlamydia, we now have a mechanistic explanation for the failure of traditional vaccines combined with an SVP-based vaccination strategy that can overcome these challenges and create a vaccine with the potential to engender the desired robust immunoprotection. (
  • This novel DNA vaccine was developed and implemented in just months via a platform that has advantages in temperature stability, storage, dose, and distribution compared to most traditional vaccines, making DNA vaccines an important tool to respond quickly to curb an emerging epidemic. (
  • This study compared two adjuvants, alum and QS-21, given separately and together in a candidate p17-based subunit AIDS vaccine, HGP-30-KLH. (
  • 2004. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. (
  • Because the components self-assemble into nanoscaled particles, they can be used as subunit-vaccine building blocks. (
  • Much attention is now focused on the development of recombinant subunit vaccines based on highly conserved pneumococcal surface proteins and virulence factors. (
  • abstract = "Development of successful vaccines against glycotopes remains a major challenge. (
  • Novartis Vaccine and Diagnostics, among other companies, developed a synthetic approach that very rapidly generates vaccine viruses from sequence data in order to be able to administer vaccinations early in the pandemic outbreak. (
  • When the H1N1 flu pandemic struck, it took about nine months to get vaccines to some places. (
  • Currently Novartis and other vaccines companies rely on the WHO to identify and distribute live reference viruses to create seasonal or pandemic vaccines. (
  • The technology could reduce the vaccine production time by up to two months, which is particularly critical in the event of a pandemic. (
  • H5N1: Can synthetic vaccines stop a flu pandemic? (
  • Influenza vaccines based on mRNA may offer a solution as sequence-matched, clinical-grade material could be produced reliably and rapidly in a scalable process, allowing quick response to the emergence of pandemic strains. (
  • Chikungunya, West Nile Virus, Pandemic Influenza, and Ebola are targets for similar synthetic DNA vaccines in future research. (
  • Most of the vaccine against that virus became available well after the pandemic was past its peak. (
  • Watertown, Mass. - December 23, 2014 - Selecta Biosciences, a clinical-stage biotechnology company developing novel drugs that use immune-modulating nanomedicines based on Synthetic Vaccine Particles (SVP™), announced today that it has been awarded a $3.2 Million grant from Skolkovo Foundation in support of Selecta's program to develop an SVP immunotherapy to treat cancers caused by infections with Human Papilloma Virus (HPV), such as cervical, head and neck cancers. (
  • With the help of the proposed approach, vaccines with a wide range of applications can be generated by means of the formation of application-specific particles through co-assembly of components with tailored functionalities. (
  • Many vaccines are based around virus-like particles (VLPs). (
  • One approach to deliver such epitope mimetics to the immune system is through the use of synthetic virus-like particles (SVLPs). (
  • In other work described at the Cambridge meeting, Pam Silver , a synthetic biologist at Harvard Medical School, presented methods for "cell-based computing," in which logic gates can be built from engineered proteins. (
  • The TriVax vaccine strategy was designed to generate large numbers of cytotoxic T-cells that would seek out the proteins preferentially expressed in the tumours. (
  • Current strategies used to ensure the effectiveness of antibacterial and antiviral vaccines rely on the attachment of pathogen-specific identification markers to carrier proteins. (
  • Now, most flu vaccines consist of hemagglutinin and neuraminidase, the two proteins covering the surface of the virus. (
  • Since variolation, conventional approaches to vaccine development are based on live-attenuated, inactivated or purified pathogen-derived components. (
  • Current vaccine design and manufacturing to meet the antigenic diversity of H3N2 viruses is challenging, and with another flu season approaching there remains a pressing need for new vaccine approaches for influenza," said lead researcher David B. Weiner, Ph.D., executive vice president and director of the Vaccine & Immunotherapy Center at The Wistar Institute, and W.W. Smith Charitable Trust Professor in Cancer Research. (
  • These fully synthetic vaccines have lower dose requirements and simplified manufacturing compared to traditional vaccine approaches. (
  • In our original research contract proposal C3013 entitled Synthetic Peptide Vaccines for the Control of Arenavirus Infections, we proposed to develop synthetic peptide based approaches. (
  • A precise understanding of the genetic differences between closely related Mycobacteria suggests rational approaches to the design of improved diagnostics and vaccines. (
  • Traditionally, bacterial vaccines are made from simply inactivated or attenuated pathogens, which are deployed to 'train' the immune system of the host. (
  • They are usually considered to be safer than vaccines from bacterial cultures. (
  • And with the first synthetic cell, we can actually send living bacterial instructions and recapitulate that at the other end. (
  • In May 2010 researchers at JCVI published results in the journal Science describing the construction of the first self-replicating, synthetic bacterial cell. (
  • While the toxicity associated with LPS prohibits its potential clinical use, MPLA is being developed as a vaccine adjuvant [2]. (
  • 2008. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. (
  • 2007. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. (
  • Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach. (
  • The latter vaccines may also be whole viruses whose nucleic acids have been modified. (
  • The overarching goals of this approach are to limit the number of vaccine reformulations that can be deployed to protect against novel H3N2 viruses. (
  • This application of synthetic DNA technology has the potential to revolutionise how we manufacture complex biologicals including recombinant viruses," said David Evans, Professor at the University's Li Ka-Shing Institute of Virology. (
  • Synthetic mRNA in liposomes can be seen as a modern, more refined, and thereby a safer version of those live attenuated RNA viruses. (
  • This work will have a broad and enduring impact on vaccine development, and the technology should be transferable to other viruses from the same family, such as poliovirus and hand-foot-and-mouth disease, a human virus which is currently endemic in South-East Asia. (
  • Vaccines are normally made from dead or modified bacteria or viruses. (
  • Synthetic virology is a branch of virology engaged in the study and engineering of synthetic man-made viruses. (
  • With synthetic live viruses, it is not whole viruses that are synthesized but rather their genome at first, both in the case of DNA and RNA viruses. (
  • Synthetic viruses have also been researched as potential gene therapy tools. (
  • Recombinant protein expression is influenced by a variety of variables associated with the choice of codons used for synthetic production. (
  • Cell- Free Production of a Functional Oligomeric Form of a Chlamydia Major Outer Membrane Protein (MOMP) for Vaccine Development. (
  • Scientists at The Wistar Institute have designed and tested the first-of-its-kind synthetic DNA vaccine against Powassan virus (POWV), targeting portions of the virus envelope protein. (
  • Therefore, in a continuing effort towards designing economical and potent vaccine candidates, the current study applied yeast surface display technology to develop an oral dengue vaccine candidate using whole recombinant yeast cells displaying the recombinant fusion protein of M cell targeting ligand Co1 fused to the synthetic consensus dengue envelope domain III (scEDIII). (
  • Plasmodium vivax circumsporozoite (CS) protein is a leading malaria vaccine candidate previously assessed in animals and humans. (
  • Using a unique approach, Wistar scientists designed optimized synthetic DNA vaccine candidates targeting a virus surface protein called glycoprotein. (
  • Polysaccharide-protein conjugate vaccines are among the safest and most successful vaccines developed during the last 30 years. (
  • Our results suggest that this novel bipartite carrier protein could be effectively used for developing anti-glycotope vaccines such as the anticancer Tn vaccine. (
  • Vaccine designs that elicit an IFN response may also help to reduce the Th2-biased response and lung inflammation associated with RSV infection. (
  • Thus, the novel nanoparticle vaccines produced in this study will have the capacity to elicit multiple mechanisms of protection against RSV infection and aberrant lung inflammation. (
  • Inovio has already conducted two separate phase I studies of its universal flu vaccine using the skin EP delivery system and generated broadly protective hemagglutination inhibition (HAI) titers against some of the most prevalent strains of H5N1 and H1N1 influenza. (
  • Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. (
  • Although two approved prophylactic vaccines against strains of HPV that cause cervical cancer are now in wide use as a measure to prevent HPV infections, these vaccines cannot be used to treat HPV-induced cancers. (
  • By developing a murine model for infection that closely mimics human skin infection, we show that the vaccine can protect against pyoderma and subsequent bacteremia caused by multiple GAS strains, including strains endemic in Aboriginal communities in the Northern Territory of Australia. (
  • Therefore, this study designed a novel synthetic anti-Ebola virus glycoprotein DNA vaccine as a strategy to expand protective breadth against diverse Ebola virus strains and evaluated the impact of vaccine dosing and route of administration on protection against lethal Ebola virus-Makona challenge in nonhuman primates. (
  • Bacille Calmette-Guérin (BCG) vaccines are live attenuated strains of Mycobacterium bovis administered to prevent tuberculosis. (
  • However, because of the inability to preserve viable bacteria (such as by freezing), this live vaccine required continued passage, eventually resulting in a profusion of phenotypically different daughter strains that are collectively known as BCG. (
  • In preparation to meet the threatened combination of H1N1 and H5N1, and previously unpredictable single strain outbreaks, in 2008 Replikins Ltd. manufactured the first completely synthetic TransFlu™ Replikins Vaccine against the common influenza strains. (
  • This review comprehensively analyzes both historical and recent studies in which synthetic carriers are used to deliver malaria vaccines. (
  • Yesterday, Valneva said it will supply process development services for GSK toward manufacturing influenza vaccines based on Valneva's EB66 ® cell line, in a collaboration partly financed by the U.S. Biomedical Advanced Research and Development Authority. (
  • 2007. Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup. (
  • 2011. Cationic liposomes as vaccine adjuvants. (
  • Dynamics of APC recruitment at the site of injection following injection of vaccine adjuvants. (
  • The vaccines are potent, safe, and do not require toxic adjuvants that limit vaccine utility. (
  • The newly published optimized conditions for Inovio's skin EP delivery systems will dramatically enhance this delivery system as an attractive method for mass vaccination by decreasing dose levels, increasing tolerability of the vaccination, and increasing the breadth of viable vaccine targets. (
  • DNA vaccination, one of the latest biotechnological breakthroughs, is the beginning of a new chapter in vaccine technology. (
  • In an effort to find an effective HPV-cancer vaccine that would eliminate existing HPV-induced cancer, Celis and Doctor Kelly Barrios-Marrugo of the University of South Florida, designed a peptide vaccination strategy called TriVax-HPV. (
  • The synthetic long vaccine is reconstituted in up to four pools (A, B, C, and D). At each vaccination time point, each of the up to four pools will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, and D - Left Leg) by subcutaneous (SC) injection. (
  • Develop a synthetic platform to support vaccination against diverse pathogens at birth by mimicking the molecular composition and release kinetics of BCG. (
  • Description A unique and modular bioinformatic process for the discovery of potential peptide vaccines against Mycobacterium tuberculosis (Mtb) has been developed by UH researchers. (
  • In the field, say the researchers, this vaccine could decrease person-to-person spread of infection in the event of an outbreak and help to protect health care workers or exposed individuals. (
  • In early October, researchers from the Perelman School of Medicine at the University of Pennsylvania reported that their Zika vaccine candidate successfully induced an immune response among participants in a phase I clinical trial. (
  • By using synthetic DNA to develop new vaccines, researchers can work at a faster time scale than when they use conventional methods. (
  • The researchers leading the GLS-5700 development believe that synthetic DNA can be utilized in other vaccine development programs. (
  • Researchers have developed a new synthetic virus that can lead to the development of a more effective vaccine against smallpox in humans. (
  • HOUSTON - Rice University researchers have delivered a scientific one-two punch with a pair of papers that detail how synthetic collagen fibers self-assemble via their sticky ends. (
  • British researchers have developed a new method for engineering a synthetic foot-and-mouth vaccine which doesn't rely on using a live virus, the BBC reports . (
  • The researchers report that foot-and-mouth disease remains a major plague of livestock, and current inactivated virus vaccines require expensive facilities for high levels of containment and refrigeration. (
  • An interdisciplinary team of Oxford University researchers has devised a new technique to speed up the development of novel vaccines. (
  • Thus, mRNA vaccines could address substantial medical need in the area of influenza prophylaxis and the broader realm of anti-infective vaccinology. (
  • In the race for a vaccine against SARS-CoV-2, the synthetic mRNA format has been shown to be the fastest one and proved to be safe and highly efficient, even at the very low dose of a few µg per injection. (
  • The development of new vaccines to treat endogenous disorders such as cancer remains a challenge, as it is not possible to create modular or tailor-made vaccines with currently available techniques. (
  • A faster way of assembling vaccines may also help with the rapid development of new vaccines against unforeseen disease outbreaks. (
  • To overcome these hurdles, Darrell Irvine, a materials scientist at the Massachusetts Institute of Technology (MIT), developed a way to trap a large amount of vaccine agents into stable capsules surrounded by special nanoparticles. (
  • Many attempts have been made to use them in vaccine development, with the size of the diamond nanoparticles (NP) being an important consideration. (
  • The team say that their technique should speed up developing new vaccines and also may help other medical applications of nanoparticles. (
  • SVLPs are made from synthetic coiled-coil lipopeptides that are designed to spontaneously self-assemble into 20-30 nm diameter nanoparticles in aqueous buffer. (
  • The most important consideration in the design of this clinical trial is to ensure the safe translation of the personalized synthetic long peptide vaccine strategy. (
  • GlaxoSmithKline (GSK) will partner with VBI Vaccines to study VBI's LPV™ Platform, a formulation and process designed to help develop vaccines and biologics with improved stability and potency. (
  • VBI said it has completed proof-of-concept studies on a number of vaccine and biologic targets that demonstrate the platform's ability to preserve potency under stress conditions. (
  • The feasibility of this approach was shown for the first time in the design of a vaccine against Neisseria meningitides that is now in phase III clinical trials. (
  • NEW YORK, April 18, 2012/PRNewswire/ -- Stemline Therapeutics, Inc. announced that trial results of two clinical studies of direct injection synthetic peptide vaccine, now being developed as SL-701, in both adults and children with advanced brain cancer were selected for late-breaking presentations at the Annual Meeting of the American Association for Cancer Research (AACR) held from March 31 to April 4, 2012 in Chicago, IL. (
  • There are several examples where conventional vaccines exacerbated infections in human clinical trials, including Chlamydia and RSV," Dr. Ulrich von Andrian, Mallinckrodt Professor of Immunopathology at Harvard Medical School and the co-founder of Selecta, said. (
  • Although further research is still required as the vaccine candidate moves through the successive stages of clinical trial, these positive results significantly advance the struggle to develop a vaccine that stops the spread of this epidemic disease. (
  • With new vaccine formulations and technology platforms, vaccine developers need to have the right processes in place to manufacture them during clinical trials and at commercial scale. (
  • New Models: How are smaller product development organizations (biotechs/non-profit/academics) manufacturing vaccine products for early and exploratory PoC clinical trials? (
  • Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal ('GI') diseases in areas of high unmet need, today announced that it submitted an Investigational New Drug ('IND') application with the U.S. Food and Drug Administration ('FDA') for its SYN-020 Intestinal Alkaline Phosphatase ('IAP') program. (
  • Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided a clinical programs update and reported financial results for the quarter ended March 31, 2020. (
  • Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company intends to release its operational highlights and financial results for the quarter ended March 31, 2020 on Tuesday, May 5, 2020, and to host a conference call the same day at 4:30 p.m. (
  • The synthesis and evaluation of potential vaccines for both cancer and HIV will be described. (
  • Synthetic lipid A from E. coli , serotype R515 (MPLAs) is a pure monophosphoryl lipid A compound produced by chemical synthesis. (
  • With companies like Twist Bioscience providing high-throughput DNA synthesis , the vaccine development timeline can meet the need for disease prevention in high risk scenarios. (
  • Green chemistry for chemical synthesis addresses our future challenges in working with chemical processes and products by inventing novel reactions that can maximize the desired products and minimize by-products, designing new synthetic schemes that can simplify operations in chemical productions, and seeking greener solvents that are inherently environmentally and ecologically benign. (
  • Advances in genome sequencing technology and oligonucleotide synthesis paved the way for construction of synthetic genomes based on previously sequenced genomes. (
  • An anti-Ebola virus DNA vaccine like this may provide an important new tool for protection, and we are excited to see what future studies will unveil. (
  • Results showed that multiple-injection regimens of the anti-Ebola virus glycoprotein DNA vaccine were 100% protective against the lethal Ebola virus-Makona challenge. (
  • Additionally, in contrast to live-attenuated vaccines, they do not revert to virulence in immunocompromised subjects, and different from genetic vaccines, they do not involve ethical questions. (
  • Alternatives to the well-established capsular polysaccharide-based vaccines against Streptococcus pneumoniae that circumvent limitations arising from limited serotype coverage and the emergence of resistance due to capsule switching (serotype replacement) are being widely pursued. (
  • The published research study was funded in part by a $25 million HIV vaccine development contract from National Institute of Allergy and Infectious Diseases and a $3.1 million National Institutes of Health Director's Transformative Research Award for universal flu vaccine development. (
  • Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. (
  • Malaria vaccine research has been ongoing since the 1980s with limited success. (
  • To sum it up, the report concludes with an all-inclusive research result on the industry chain of Synthetic Peptide Vaccine Sales Industry facilitating the market participants in making well-informed strategic decisions. (
  • We may need an approach that can get you millions and even billions of doses," said immunologist and physician Lynda Stuart, who directs the foundation's vaccine research. (
  • Gates announced last month that it will funnel $60 million to Covid-19 research, including vaccines. (
  • Watch Jeff Ulmer, Head of Preclinical Research and Development, US, explain how SAM could disrupt the way we make vaccines. (
  • The large share of the segment can be attributed to the rising demand for synthetic DNA, synthetic RNA, and synthetic genes, which are used in a wide range of research applications. (
  • WATERTOWN, Mass.--( BUSINESS WIRE )-- Selecta Biosciences, Inc. , and JDRF , announced today that they have extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop a Synthetic Vaccine Particle (SVP™) immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes. (
  • The research could lead to synthetic vaccines that protect people from the flu, HIV and other diseases. (
  • Ceva Santé Animale was founded in 1999 and is a global veterinary health company, focused on research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry. (
  • The results of our research pave the way towards production of a novel synthetic vaccine to help bring about the global elimination of poliomyelitis. (
  • The Wistar Institute is an international leader in biomedical research with special expertise in cancer and infectious disease research and vaccine development. (
  • Despite several large research efforts, no vaccines have advanced far enough in development to be deemed safe in humans and effective for Zika prevention. (
  • How are non-profits and academics de-risking earlier staged vaccine research before further development? (
  • The research showed that the synthetic horsepox virus could provide vaccine protection in a mouse model of poxvirus infection. (
  • GSK's research collaboration with VBI marks the second vaccine-related partnership for the pharma giant in as many days. (
  • Professor Pol Besenius, a chemist working at Johannes Gutenberg University Mainz (JGU), has secured funding from the European Research Council (ERC) for the development of fully synthetic vaccines. (
  • Furthermore, the findings from this project are expected to have an impact on the design and preparation of vaccine candidates in academic and industrial research laboratories. (
  • George Korch Jr, PhD, acting principal deputy with the ASPR, said the issues that would need discussion in a working group would be possible design of vaccine research protocols, the risks and benefits, and ethics surrounding its use. (
  • Another area of medicinal research in which the Janda laboratory has made contributions encompasses techniques to create molecular diversity, uncover active components from complex mixtures and the separation of synthetic targets by phase tagging. (
  • This review summarise the current stand and future perspective on synthetic peptide-based vaccines. (
  • It's not only the first malaria vaccine, but the first against any parasitic disease of humans. (
  • Another constraint to the use of epitope vaccines was their restriction to some MHC or HLA phenotypes. (
  • Thus synthetic epitope vaccines may better meet the requirements of the regulatory agencies since they have lower costs and are easier to produce. (
  • The results show that SVLPs combined with synthetic epitope mimetics may have potential for the development of an effective vaccine against Streptococcus pneumoniae. (
  • These technologies should play an important role in Inovio's quest to develop paradigm changing vaccines and immune therapies for several major diseases. (
  • This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. (
  • In this Review, we discuss efforts to develop a malaria vaccine from LSPs, among other clinically directed work. (
  • Consistent with our company's strategy for infectious disease indications, we will actively seek value-adding partners with whom to develop and commercialize SVP for mucosal vaccines. (
  • Early attempts to develop a formalin- inactivated vaccine (FI-RSV) resulted in disease enhancement following environmental exposure to RSV. (
  • With our partners, we seek to develop a next generation of vaccines and biologics with improved stability characteristics that allow for consistently safe and effective administration in both established and emerging markets," VBI president and CEO Jeff Baxter said in a statement. (
  • The anticipation of 80 million cases of tuberculosis in the coming decade, an increasing proportion of which are likely to be drug-resistant, has revived efforts to develop a new vaccine ( 1 ). (
  • Karl Brune, leading the work in Professor Mark Howarth's lab in Oxford's Department of Biochemistry explained: 'Current techniques to develop VLP-based vaccines take time and do not always work. (
  • The aim of the current study was to develop a cancer vaccine formulation for treatment of human papillomavirus (HPV)-induced malignancies. (
  • This project will use an innovative nanoparticle technology to produce novel vaccine candidates for respiratory syncytial virus. (
  • This technology is now being used to investigate novel vaccine strategies. (
  • The vaccine platform can potentially be applied to all different kinds of infectious diseases," Moon said. (
  • Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. (
  • This new POWV vaccine candidate, described in a paper published today in PLOS Neglected Infectious Diseases , is one of many emerging infectious disease DNA vaccine discoveries being advanced by the Vaccine and Immunotherapy Center at The Wistar Institute. (
  • Kar Muthumani, Ph.D., former associate professor and director of the Laboratory of Emerging Infectious Diseases at The Wistar Institute, and senior author on the study, collaborated with the laboratory of David B. Weiner, Ph.D., executive vice president and director of Wistar's Vaccine and Immunotherapy Center, to design and test this synthetic DNA vaccine. (
  • Given the risk of serious complications from POWV and the 300% increase in incidence of POWV infection over the past 16 years, we will continue efforts to advance this urgently needed emerging infectious disease vaccine candidate towards the clinic,' said Weiner. (
  • The accelerated timeframe afforded by synthetic DNA is particularly advantageous in trying to combat emerging infectious diseases and epidemics. (
  • Synthetic DNA vaccines, such as this Zika vaccine candidate our team has developed, are an important approach to preventing emerging infectious diseases," David Weiner, PhD, co-lead author of the synthetic DNA Zika vaccine study, said in a news release . (
  • The application of this innovative approach to RSV vaccine development will also impact vaccine development for other infectious diseases. (
  • I will focus on a radical new design approach to produce fully synthetic, supramolecular vaccines," explained Besenius. (